|
Erratum: Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study
Oct 22, 2026 Erratum: Modernizing Drug Development for Exceptional Therapies in High-Unmet Need Diseases: A Call for Pragmatism and Patient Centricity Oct 22, 2026 Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Oct 20, 2026 Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial Oct 19, 2026 Time-of-Day Immunotherapy: Why the Field Still Needs Randomized Evidence Oct 19, 2026 Effectiveness of a Multisite Oncology Financial Navigation Intervention: The Lessening the Impact of Financial Toxicity Clinical Trial Oct 16, 2026 Promise and Challenge of Personalized Lung Cancer Screening Oct 16, 2026 Beyond Phlebotomy: Iron Homeostasis in the Next Phase of Polycythemia Vera Management Oct 16, 2026 Expert Histopathologic Evaluation and Molecular Analyses for Ambiguous Cutaneous Melanocytic Tumors Oct 15, 2026 First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies Oct 15, 2026 Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial Oct 14, 2026 Neurodevelopmental Blueprint in Gliomas: Toward an Ontogenetic Multimodal Integrated Therapy Oct 14, 2026 Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study Oct 14, 2026 Clinical Trial Prediction Markets Oct 14, 2026 Radiation Oncology at a Crossroads: Interpreting the Evidence on Proton Versus Photon Radiotherapy for Oropharyngeal Cancer Oct 14, 2026 Prescription Does Not Ensure Patient Access: Progress and Remaining Challenges in Addressing Access Barriers to Specialty Oral Anticancer Medications Oct 14, 2026 Erratum: Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study Oct 14, 2026 Erratum: Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients Oct 14, 2026 The Boy Who Became a Tiger Oct 13, 2026 VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy Oct 13, 2026 |
When Survival Separates Journal of Clinical Oncology, Volume 44, Issue 31, Page 3070-3071, November 2026. <br/> 2026-11-01T07:00:00Z Bridging the Gap: Clinical Integration of Thrombopoietin Receptor Agonists in GI Cancer–Associated Chemotherapy-Induced Thrombocytopenia Journal of Clinical Oncology, Volume 44, Issue 31, Page 2985-2989, November 2026. <br/> 2026-11-01T07:00:00Z Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care Journal of Clinical Oncology, Volume 44, Issue 31, Page 3026-3035, November 2026. <br/> 2026-11-01T07:00:00Z First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT) Journal of Clinical Oncology, Volume 44, Issue 31, Page 3015-3025, November 2026. <br/> 2026-11-01T07:00:00Z Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial Journal of Clinical Oncology, Volume 44, Issue 31, Page 3036-3047, November 2026. <br/> 2026-11-01T07:00:00Z Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4 Journal of Clinical Oncology, Volume 44, Issue 31, Page e152-e169, November 2026. <br/> 2026-11-01T07:00:00Z Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL Journal of Clinical Oncology, Volume 44, Issue 31, Page 2999-3005, November 2026. <br/> 2026-11-01T07:00:00Z Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial Journal of Clinical Oncology, Volume 44, Issue 31, Page 3006-3014, November 2026. <br/> 2026-11-01T07:00:00Z Current Management of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in a Changing Landscape Journal of Clinical Oncology, Volume 44, Issue 31, Page 3061-3069, November 2026. <br/> 2026-11-01T07:00:00Z Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer Journal of Clinical Oncology, Volume 44, Issue 31, Page 3048-3060, November 2026. <br/> 2026-11-01T07:00:00Z Care Gap: Identifying and Bridging Barriers in Primary Palliative Care Journal of Clinical Oncology, Volume 44, Issue 31, Page 2994-2998, November 2026. <br/> 2026-11-01T07:00:00Z Corticosteroids in Glioblastoma Management: A Reconsideration of a 65-Year Practice Journal of Clinical Oncology, Volume 44, Issue 31, Page 2990-2993, November 2026. <br/> 2026-11-01T07:00:00Z Postrecurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603 Journal of Clinical Oncology, Volume 44, Issue 31, Page 3072-3072, November 2026. <br/> 2026-11-01T07:00:00Z Time-Varying Effects of Copy Number Alteration Clustering: Methodologic Concerns in Survival Analysis of Relapsed/Refractory Germ Cell Tumors Journal of Clinical Oncology, Volume 44, Issue 31, Page 3074-3075, November 2026. <br/> 2026-11-01T07:00:00Z Erratum: Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial Journal of Clinical Oncology, Volume 44, Issue 31, Page 3078-3078, November 2026. <br/> 2026-11-01T07:00:00Z Erratum: Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study Journal of Clinical Oncology, Volume 44, Issue 31, Page 3078-3078, November 2026. <br/> 2026-11-01T07:00:00Z |
Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. 2026-10-24
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer Among patients with HER2-positive advanced breast cancer, the HER2-targeted bispecific antibody anbenitamab plus albumin-bound docetaxel led to 24-month progression-free survival of 58.5%, as compared with 34.4% with standard therapy. 2026-10-24
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. 2026-10-24
Targeting HER2 — A Triumph of Science Scientific progress in oncology has been substantially advanced through mechanistic discovery. Human epidermal growth factor receptor 2 (HER2) was first established as an oncogenic driver by Slamon et al. in 1987, a discovery that catalyzed the development of highly effective, life-prolonging targeted therapies.1 Substantial progress has since been... 2026-10-24
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. 2026-10-22
Helicobacter pylori Infection — Advances, Challenges, and the Road Ahead The discovery of H. pylori has advanced the prevention and treatment of gastritis, peptic ulcers, and gastric cancer. Progress has been made in the research of H. pylori infection. These advances are discussed in this review. 2026-10-22
Reengineering Coagulation with a Bispecific Antibody Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa, who developed a prophylactic therapy for hemophilia A, have received the 2026 Lasker–DeBakey Clinical Medical Research Award. 2026-10-22
Case 30-2026: A 52-Year-Old Man with Vision Loss in the Left Eye A 52-year-old man with metastatic small-cell lung cancer was evaluated in the ophthalmology clinic because of vision loss in the left eye. A blood cytomegalovirus DNA viral load was 348 IU per milliliter. A diagnosis was made. 2026-10-22
In Vivo Aquaporin-1 Circular RNA Therapy for Radiation-Induced Xerostomia In a phase 1 study, RXRG001, a circular RNA encoding aquaporin-1, was administered to six patients with radiation-induced xerostomia. Measures of salivary flow improved, and adverse events were of grade 1 or 2 and transient. 2026-10-22
Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL In a trial involving adults with Ph-positive acute lymphoblastic leukemia, 24-month event-free survival was 86% with the TKI–immunotherapy combination ponatinib–blinatumomab and 67% with imatinib plus chemotherapy. 2026-10-15
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema In a phase 3, randomized trial of lonvo-z, an in vivo gene-editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. 2026-10-15
Case 29-2026: A 39-Year-Old Man with Abdominal Pain, Foot Drop, and a Spinal Mass A 39-year-old man, who was an Iraq War veteran with exposure to burn pits, was admitted to the hospital with hypertension, abdominal pain, and foot drop. Imaging showed a thoracic spinal mass. A diagnosis was made. 2026-10-15
Flushing in Carcinoid Syndrome A 44-year-old man was admitted for the management of carcinoid syndrome, which had been diagnosed 4 years earlier. On examination, mottled, violaceous, blanchable flushing was seen across the face and torso. 2026-10-15
Adapting to Genomic Medicine Hereditary angioedema is a disorder characterized by unpredictable, transient episodes of swelling and pain of various body parts. It can be life-threatening if the airway is involved. Current therapies include several different products that are administered prophylactically or at the onset of symptoms, and the prophylactic products must be administered... 2026-10-15
IARC Perspective on Lung Cancer Screening The 21st volume of the IARC Handbooks summarizes and evaluates evidence for the benefits and harms of lung cancer screening with low-dose CT or chest radiography and assesses tools and strategies to improve screening. 2026-10-15
Chemotherapy-free Treatment of Ph-Positive ALL It would be rare for anyone who has undergone intensive, multicycle, multiagent chemotherapy followed by allogeneic hematopoietic stem-cell transplantation to agree with Nietzsche’s personal view that “Out of life’s school of war, what does not kill me, makes me stronger.” Even though our past approaches to treating patients with the... 2026-10-15
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis In a trial of a blood-based multicancer early-detection test added to usual care, the incidence of stage III or IV cancer after three rounds of screening did not differ significantly from that with usual care alone. 2026-10-08
Advances in Systemic Treatment of Breast Cancer This review summarizes advances in therapy, including approval or expanded use of targeted agents, improved outcomes with antibody–drug conjugates and immunotherapy, and growing reliance on molecular profiling. 2026-10-08
Case 28-2026: A 19-Year-Old Woman with Fever, Cervical Lymphadenopathy, and Leukopenia A 19-year-old woman presented with fever and cervical lymphadenopathy. The white-cell count was 2900 per microliter (reference range, 4000 to 11,000), and the lactate dehydrogenase level was elevated. A diagnosis was made. 2026-10-08
A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer The diagnosis of cancer at earlier stages is generally associated with improved survival. Detecting circulating tumor–derived cell-free DNA (cfDNA) is an established method of monitoring the response to therapy for many cancer types, particularly hematopoietic and metastatic cancers — which leads to the question of whether screening for cfDNA in... 2026-10-08
|
|
|
| |||
|
[Editorial] Sweating the details in exercise oncology
The benefit of exercise alongside cancer treatment and recovery has primarily rested on association. However, two randomised trials, CHALLENGE and STAMINA, now supply the causal evidence that exercise oncology lacked. The pressing question is now one of implementation. STAMINA has already led to free exercise programmes for men undergoing treatment for prostate cancer in the UK and the European Society for Medical Oncology has updated their guidelines as a result of the CHALLENGE study. Sun, 01 Nov 2026 00:00:00 -0700
[Comment] Iberdomide for minimal residual disease-negative myeloma—from underdog to the spotlight The introduction of thalidomide and its derivatives—lenalidomide, followed by pomalidomide—has improved the therapeutic arsenal for multiple myeloma for more than two decades. These immunomodulators bind to cereblon, a component of the CRL4-cereblon E3 ubiquitin ligase complex, which results in the targeted degradation of the transcription factors Ikaros and Aiolos.1,2 Iberdomide belongs to the next generation of drugs, known as cereblon E3 ligase modulators. Its chemical structure is extended by an additional benzyl moiety bearing a morpholine group—which increases the molecular volume and the contact surface with cereblon, thereby enhancing its affinity and degradation potency compared with conventional immunomodulators. Sun, 01 Nov 2026 00:00:00 -0700
[Comment] Time to say goodbye to full-field digital mammography in population-based screening? 51 (96%) of 53 countries in the WHO European Region have national breast cancer screening programmes. Globally, 63% of all nations have established breast cancer screening programmes.1 Most of the European screening programmes are organised nationally and are population-based, focusing on women older than 50 years.1 Full-field digital mammography is the gold standard screening modality used in these programmes because of its clinical efficiency and cost-effectiveness.2 Fri, 09 Oct 2026 22:30:01 +0000
[Comment] Comprehensiveness of national cancer control plans Cancer poses a disproportionate disease burden across different country populations. Beyond large international differences in cancer incidence, cancer survival varies globally, even between countries within the same continent or among those with publicly funded health-care systems.1–3 Therefore, much research in recent years has rightly focused on how countries with a relatively poor record in cancer control could narrow the gap separating them from high-performing peers. Sun, 01 Nov 2026 00:00:00 -0700
[Comment] The unfulfilled promise of effective cancer medicines priced beyond reach Every year, pivotal clinical trials are reported, showing major advances in cancer treatment. At the American Society of Clinical Oncology (ASCO) 2026 conference, results from the RASolute302 trial for patients with advanced pancreatic cancer established daraxonrasib, a RAS(ON) inhibitor, as a watershed moment in oncology.1 Among previously treated patients, daraxonrasib improved median overall survival by 7 months compared with chemotherapy and improved quality of life. Given that pancreatic cancer is among the most lethal of all cancers, the target was hitherto considered undruggable, and that the disease is accompanied by considerable suffering, this treatment was appropriately celebrated as a landmark success of drug development. Sun, 01 Nov 2026 00:00:00 -0700
[Comment] Rare earth elements and the fragile promise of cancer theranostics Radionuclide theranostics is transforming oncology by enabling more personalised treatment based on tumour biology. The approach pairs tumour-specific vectors with diagnostic and therapeutic radionuclides. Theranostics enables clinicians to confirm tumour targeting via molecular imaging before delivering targeted radiation with the same vector. Over the past decade, this approach has transformed treatment for neuroendocrine tumours and prostate cancer and is now expanding into additional malignancies and earlier stages of disease. Sun, 01 Nov 2026 00:00:00 -0700
[Comment] Why childhood cancer medicines need market shaping led by the Global Platform: toward market transformation The majority of children diagnosed with cancer do not have access to essential medicines.1 To address this reality, the Global Platform for Access to Childhood Cancer Medicines (Global Platform) was launched in February, 2025, by WHO and St Jude Children's Research Hospital, in collaboration with UNICEF and the Pan American Health Organization (PAHO).2 Tue, 15 Sep 2026 22:30:01 +0000
[Correspondence] From biomarker actionability to surveillance utility in SERENA-6 Nicholas C Turner and colleagues1 report extended SERENA-6 results showing sustained benefit in progression-free survival (hazard ratio [HR] 0·45, 95% CI 0·34–0·59; nominal p<0·0001) and improved second progression-free survival (HR 0·63, 0·46–0·86; p=0·0037) after switching from an aromatase inhibitor to camizestrant when ESR1 mutations were detected in circulating tumour DNA (ctDNA).1 These findings support ESR1 mutation as an actionable biomarker. However, treatment efficacy in patients with detected ESR1 mutations does not, by itself, establish the population-level utility of serial surveillance, which depends on its intended use and net effects across all patients tested. Sun, 01 Nov 2026 00:00:00 -0700
[Correspondence] BCG-unresponsive non-muscle-invasive bladder cancer We read with great interest the BOND-003 Cohort C results reported by Mark D Tyson and colleagues,1 showing durable complete responses with intravesical cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ. Sun, 01 Nov 2026 00:00:00 -0700
[Correspondence] BCG-unresponsive non-muscle-invasive bladder cancer Mark D Tyson and colleagues1 report centrally confirmed complete response at any time in 83 (75%) of 110 efficacy-evaluable patients receiving intravesical cretostimogene grenadenorepvec for BCG-unresponsive, carcinoma in situ-containing non-muscle-invasive bladder cancer in BOND-003 Cohort C. They also report cystectomy-free survival of 89% at 12 months and 81% at 24 months.1 These results are encouraging. However, for patients considering bladder preservation, the relevant outcome is retention of the bladder without high-grade disease, rather than organ retention alone. Sun, 01 Nov 2026 00:00:00 -0700
[Correspondence] BCG-unresponsive non-muscle-invasive bladder cancer – Authors’ reply We thank Pietro Scilipoti and colleagues and Man Sun and colleagues for their interest in our Article on BOND-003 Cohort C.1 Sun, 01 Nov 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2025; 26: 898–910 Kirby AM, Finneran L, Griffin CL, et al. Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 2025; 26: 898–910—In this Article, in table 1, the row of data for the reduced-dose group under the heading Any breast cancer event (intention-to-treat population) has been amended. In the third paragraph of the Results, sentence three should have read “63 (3%) participants developed contralateral breast primary cancers (24 [4%] in the whole-breast group, 20 [3%] in the reduced-dose group, and 19 [3%] in the partial-breast group), 53 (84%) of which were invasive...”, sentence four should have read “Non-breast second primary cancers were reported for 159 (8%) patients (62 [9%] in the whole-breast group, 57 [8%] in the reduced-dose group…”, sentence six should have read “Three breast angiosarcomas were reported...”, and sentence nine should have read “Breast cancer-related events of any kind were reported for 170 patients… with a 10-year breast cancer-free-interval in…91·8% (89·3–93·7) in the reduced-dose group…”. Sun, 01 Nov 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2025; 26: e423–35 Concin N, Matias-Guiu X, Cibula D, et al. ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol 2025; 26: e423–35. The appendix of this Policy Review has been corrected as of Oct 26, 2026. Sun, 01 Nov 2026 00:00:00 -0700
[News] 70th IAEA General Conference Malawi's National Cancer Centre, opened in July, 2025, with support from the International Atomic Energy Agency's (IAEA) Rays of Hope initiative, is intended to bring several cancer services together in one facility. The centre provides radiotherapy and brachytherapy, alongside surgery and chemotherapy, reducing the need for patients to seek different parts of their treatment elsewhere. The centre was among developments highlighted at the 70th IAEA General Conference, held at the Vienna International Centre on Sept 14–18, 2026, as countries discussed efforts to expand cancer diagnosis and treatment. Thu, 24 Sep 2026 22:30:03 +0000
[News] India reaches 8 million milestone in HPV campaign Earlier this month, India surpassed 8 million doses of the human papillomavirus (HPV) vaccine, Gardasil-4, administered under a nationwide campaign launched earlier this year. The Ministry of Health and Family Welfare described the milestone as an important step forward in their goal of reducing cervical cancer in a country that accounts for roughly a quarter of global deaths from the disease. Four states have already reached 100% coverage of their target populations. However, the national picture is uneven, and experts say sustaining momentum will require overcoming vaccine hesitancy, misinformation, and the logistical demands of reaching eligible girls across a vast and diverse country. Thu, 24 Sep 2026 22:30:03 +0000
[News] US EPA repeals emission limits On Sept, 14, 2026, the US Environmental Protection Agency (EPA) under the Trump administration announced a rollback of Biden-era rules limiting greenhouse gas emissions from the country's coal-burning and gas-fired power plants. The EPA also proposed scrapping all other greenhouse gas emissions rules for the power sector implemented by the Biden administration, arguing that the regulations exceeded the agency's authority under the Clean Air Act. Thu, 24 Sep 2026 22:30:02 +0000
[News] Could Brazil's tuberculosis network detect lung cancer earlier? A 6 month landscape assessment has explored whether Brazil could use its tuberculosis and primary health-care infrastructure to detect lung cancer earlier. The assessment covered three states (Rio de Janeiro, Pernambuco, and Amazonas) and was conducted by PATH and Global Health Strategies. The project was funded by the Bristol Myers Squibb Foundation. Thu, 01 Oct 2026 22:30:03 +0000
[News] New UK National Cancer Board The UK Government has formed a new National Cancer Board to drive delivery of its 2026 National Cancer Plan, a strategy blueprint aimed at transforming cancer care and outcomes in England by 2035. Thu, 01 Oct 2026 22:30:02 +0000
[News] Viet Nam considers health insurance for cancer screening Viet Nam's Ministry of Health wants to add screening and early diagnosis for seven cancers to services reimbursed by the Health Insurance Fund, potentially shifting a system that has largely financed cancer care after diagnosis towards earlier detection. But the draft decree would phase in coverage and leave the Ministry of Health to define target groups, services, and payment levels, with implementation tied to the fund's ability to pay. Thu, 01 Oct 2026 22:30:08 +0000
[News] 2026 ASTRO Annual Meeting Historically, prophylactic cranial irradiation (PCI) is associated with improved survival but increased neurological toxicity. Paul Brown (Mayo Clinic, Rochester, MN, USA) presented results from the phase 3 SWOG S1827 MAVERICK trial, comparing standard-of-care, PCI plus MRI, with MRI surveillance alone in 304 randomly assigned patients with limited and extensive-stage small-cell lung cancer (SCLC) who had completed initial therapy. The median follow-up was 22 months and the primary endpoint, cognitive failure-free survival, was significantly better in the MRI only group (HR 0·60, 90% CI 0·46–0·78; p=0·001). Thu, 01 Oct 2026 22:30:03 +0000
[News] Impact of the Trump Administration on the Affordable Care Act On Sept 22, 2026, the US Government cancelled more than 760 000 people's government-subsidised health insurance policies, contending they were fraudulently obtained on the Federal Health Insurance Marketplace. As many as 440 000 other enrolments are still under investigation, officials said. Thu, 08 Oct 2026 22:30:03 +0000
[News] Europe has fallen behind in number of oncology trials The proportion of the world's oncology trials delivered within Europe has fallen from 41% in 2008 to 21% in 2023, according to a new report by the European Cancer Organisation (ECO). Thu, 15 Oct 2026 22:30:01 +0000
[News] Russia slashes federal cancer funding to spend on defence Cancer experts fear a rise in cancer cases in Russia if a draft 2027 budget proposing a sharp cut of more than 90% in federal cancer funding is pushed through parliament. Thu, 15 Oct 2026 22:30:01 +0000
[Perspectives] Beyond words: the Art of Living Some places shape not only the careers we build, but the people we become. For me, that place is the Cape Breton Cancer Centre (Sydney, NS, Canada). In 2001, I began my career as a radiation therapist, never imagining that this cancer centre would become one of life's greatest teachers. Sun, 01 Nov 2026 00:00:00 -0700
[Perspectives] Alison Berner: Connecting oncology and gender medicine It was a 2015 Editorial in The Lancet Oncology discussing cancer in the transgender community, that set Alison Berner (Queen Mary University of London, London, UK) on her unique career path.1 The Editorial cited a piece of research in people with HIV, which she realised meant there was no relevant papers in transgender people with cancer to draw on. Sun, 01 Nov 2026 00:00:00 -0700
[Perspectives] There is beauty after breast cancer Joanne Tinker remembers searching online for what a mastectomy would look like, convinced she was about to be mutilated. She was not. The gap between fear and reality is what a new exhibition in Ilkley (UK) sets out to close. Sun, 01 Nov 2026 00:00:00 -0700
[Articles] Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial Iberdomide, daratumumab, and dexamethasone significantly improved MRD-negative complete response compared with daratumumab, bortezomib, and dexamethasone. The most common grade 3 or grade 4 adverse events were haematological events and infections, which were mostly manageable with standard supportive care. These findings support iberdomide, daratumumab, and dexamethasone as an efficacious treatment option for patients with relapsed or refractory multiple myeloma with the potential to be administered across diverse care settings. Fri, 25 Sep 2026 14:00:02 +0000
[Articles] Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial TOSYMA-2 indicates that about a quarter of invasive interval cancers occurring with digital mammography over 2 years might be avoided with digital breast tomosynthesis plus s2D mammography screening. Although the primary outcome of TOSYMA-2 did not reach statistical significance, this large, randomised trial adds substantial evidence to the use of digital breast tomosynthesis plus s2D mammography in breast cancer screening. Fri, 09 Oct 2026 22:30:01 +0000
[Articles] Assessment of comprehensiveness of national cancer control plans using a multiagent artificial intelligence model: a global analysis Our analysis suggests that NCCP comprehensiveness varies substantially between countries with consistent weaknesses in financing, outcome measurement, and contextual analysis. A shared health systems framework and scalable AI appraisal tools, such as PRISM, could support more complete, comparable, and actionable plans to strengthen cancer control globally by providing the possibility for rapid analysis of comprehensiveness of NCCPs and generation of timely, achievable, and evidence-informed, context-specific plans that use the latest data. Sun, 01 Nov 2026 00:00:00 -0700
[Articles] Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study The risk–benefit ratio observed in the DALY 2-EU study supports consideration of zamto-cel as a second-line standard treatment option for patients with relapsed or refractory large B-cell lymphoma who are ineligible for transplantation. Sun, 01 Nov 2026 00:00:00 -0700
[Articles] Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial Neoadjuvant niraparib showed anti-tumour activity and enabled R0 resection in selected patients with HRD-positive advanced ovarian cancer who were initially unsuitable for primary debulking surgery. This strategy remains investigational and requires randomised validation against standard platinum-taxane neoadjuvant chemotherapy. Wed, 07 Oct 2026 22:30:05 +0000
[Articles] Global uptake of essential cancer medicines with and without complex genomic diagnostics: a retrospective observational study These findings should be interpreted as evidence of associations not causality, suggesting differences in quantity uptake of essential cancer medicines along two structural dimensions: fewer countries showed uptake of essential cancer medicines in lower-GDP countries than in middle-GDP and high-GDP countries and medicines requiring complex genomic diagnostics had lower uptake, with the lowest uptake in lower-GDP countries. The results suggest that, as precision oncology medicines become increasingly represented in the WHO EML, EML inclusion alone could be insufficient to enable patient access. Fri, 25 Sep 2026 03:10:02 +0000
[Articles] Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial In this interim analysis, short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival in patients with locally advanced rectal cancer, with a safety profile similar to long-course chemoradiotherapy followed by CAPOX. Comparison of this promising new treatment strategy with contemporary total neoadjuvant therapy strategies is warranted. Sun, 25 Oct 2026 10:15:00 +0000
[Articles] Global health expenditures on cancer control: a cross-sectional analysis Our findings indicate high variability of per-capita health expenditure on cancer control globally and generally low expenditure levels, particularly in lower-middle-income and low-income countries and territories. The paucity of publicly available expenditure data on cancer control indicates the need for production of detailed NHAs that include disease-specific expenditures to ensure availability of regular, comparable, and reliable data. Tue, 22 Sep 2026 22:30:02 +0000
[Policy Review] Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer The goal of adjuvant systemic therapy after locoregional treatment of cancer is to increase the probability of cure by eradicating micro-metastases. Adjuvant treatment adds side-effects and can impair health-related quality of life (HRQOL); this must be balanced against a reduction in the probability of recurrence, which has a substantial negative effect on HRQOL. Since many adjuvant therapies lead to small gains in relapse-free or overall survival, the severity and duration of treatment-related side-effects and their impact on patient functioning and overall HRQOL are relevant to clinical decision making. Tue, 29 Sep 2026 22:30:01 +0000
[Policy Review] Development of the Children's Oncology Group long-term follow-up guideline for cancer genetics evaluation in childhood cancer survivors Up to 12% of childhood cancer survivors have an underlying cancer predisposition syndrome (CPS). As a result, these childhood cancer survivors are at increased risk for developing and succumbing to subsequent malignant neoplasms. Identifying childhood cancer survivors with CPS is essential to improving overall outcomes by informing tailored approaches to cancer screening, treatment, and, for some, risk-reducing interventions. Despite these potential benefits, it is often unclear which childhood cancer survivors warrant referral for genetic counselling and germline genetic testing. Sun, 01 Nov 2026 00:00:00 -0700
[Policy Review] Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations Patients with de novo metastatic nasopharyngeal carcinoma were historically deemed incurable and treated with palliative intent. Emergence of potent systemic therapy in combination with local treatment for both locoregional and metastatic diseases has enabled long-term survival in some patients. This international guideline was developed through consensus-building by 54 experts from 46 centres across 18 countries or regions and endorsed by 17 oncology organisations. 32 recommendations across seven clinical domains were formulated, including 29 strong (≥80% agreement [consensus] or high quality of evidence) and three conditional recommendations (67–79% agreement). Sun, 01 Nov 2026 00:00:00 -0700
|
Maintenance therapy with low dose cyclophosphamide does not increase the risk of second malignancies: The European Pediatric Soft Tissue Sarcoma Study Group RMS2005 study experience
Tue, 27 Oct 2026 07:50:54 -0700 Structured rehabilitation for terminal cancer: Aligning the evidence with the setting that funds it Tue, 27 Oct 2026 07:47:05 -0700 Reply to “Structured rehabilitation for terminal cancer: Aligning the evidence with the setting that funds it” Tue, 27 Oct 2026 07:40:35 -0700 Population‐level diagnostic and radiation treatment trends of low‐risk prostate cancer Mon, 26 Oct 2026 00:01:13 -0700 Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patients Postdiagnosis weight trajectory and metabolic health are important prognostic factors for nonmetastatic RCC. Weight stability and absence of diabetes were associated with more favorable outcomes. Incorporating repeated BMI measurements and diabetes status may improve risk stratification during RCC survivorship. Fri, 23 Oct 2026 11:43:57 -0700 Generative artificial intelligence in medical oncology: A clinically focused narrative review of large language, vision‐language, and agentic artificial intelligence systems Fri, 23 Oct 2026 10:43:57 -0700 Risk factors and outcome of children and young adults with initially unresected nonrhabdomyosarcoma soft tissue sarcoma: An analysis from the International Soft Tissue Sarcoma Consortium Outcomes were more favorable with the combination of chemotherapy and RT (pre‐ or postoperative) versus no RT for initially unresected NRSTS. Patients with large synovial sarcoma may benefit from contemporary trial designs incorporating more of a risk‐based directed neoadjuvant chemotherapy and RT approach. Higher R0 margin status rates were achieved in protocols with specified preoperative RT, which resulted in improved outcomes. Thu, 22 Oct 2026 06:50:16 -0700 Issue Information Thu, 22 Oct 2026 06:43:28 -0700 |
||
|
| |||
|
[Editorial] Personalising AML treatment: beyond age and fitness
Over the past couple of decades, the number of treatment options for patients with acute myeloid leukaemia has accelerated; however, most patients still do not survive long-term, with 5-year overall survival around 30%. For younger and functionally fit patients, the predominant front-line therapy has remained unchanged for half a century: intensive induction chemotherapy that includes cytarabine and anthracyclines (the 7+3 regimen). For older patients or those not able to undergo intensive chemotherapy, a combination of hypomethylating agent and venetoclax is now the standard front-line therapy, spearheaded by the VIALE-A trial in 2020. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia Nicolò Peccatori and colleagues provide evidence for inotuzumab ozogamicin in paediatric very-high-risk first-relapse B-cell acute lymphoblastic leukaemia.1 The data support a less toxic bridge to haematopoietic stem cell transplantation (HSCT), but the response denominators support a more specific clinical interpretation: inotuzumab ozogamicin is best viewed as cycle-1 molecular triage, not prolonged reinduction or a replacement for UK ALLR3 chemotherapy. Because ITCC-059 was a single-arm study and its statistical design was modified from 43 to 31 patients while increasing the alpha-error to 10%, comparative claims should be reframed as response-adapted sequencing. Wed, 09 Sep 2026 22:30:04 +0000
[Correspondence] Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply We appreciate discussing the ITCC-059 results in response to Xiaogang Hao and colleagues. Wed, 09 Sep 2026 22:30:01 +0000
[In Focus] From approval to practice: are clinicians and health systems ready for gene therapy in sickle cell disease? Once a scientist's dream, gene therapy for sickle cell disease has now entered clinical practice. Autologous gene-based therapies offer a potential curative option for a disease that affects approximately 7·7 million people worldwide and remains associated with substantial morbidity, premature mortality, and entrenched health inequities. Regulatory approval, however, represents only the first step in a much longer translational pathway. Experience from other high-cost innovations suggests that without concurrent investment in implementation, workforce preparation, and financing, access could remain uneven or delayed. Thu, 01 Oct 2026 00:00:00 -0700
[In Focus] Vernon Louw: expanding access to clinical haematology in Africa Vernon Louw was not that interested in haematology at first. As an undergraduate he had found the teaching “very laboratory based” and he “struggled to connect it with the patients behind the results”. This sentiment changed when he began treating patients with haematological malignancies as a registrar in internal medicine. “I came to appreciate that haematology combines complex diagnostic reasoning, laboratory science, and long-term relationships with patients in a particularly compelling way”, he recalled. Thu, 01 Oct 2026 00:00:00 -0700
[In Focus] Integrating sexual health into sickle cell disease care Sexual health is a fundamental component of overall wellbeing, yet it remains one of the least addressed dimensions of care for people living with sickle cell disease. At the ASCAT 2025 meeting in London, UK, ERN-EuroBloodNet and RADeep registry convened a 3-day patient educational workshop dedicated to this topic. The sessions brought together 27 people living with sickle cell disease and a multidisciplinary team comprising one obstetrician, one internist, two haematologists, and two psychologists, creating an intergenerational and intercultural space, with 13 countries represented to exchange perspectives. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2) To our knowledge, this is first clinical study of a Bruton tyrosine kinase inhibitor, rilzabrutinib, in warm autoimmune haemolytic anaemia. Rilzabrutinib showed robust overall and durable haemoglobin response and favourable safety in patients with previously treated warm autoimmune haemolytic anaemia. Rilzabrutinib has the potential to treat the underlying pathophysiology of warm autoimmune haemolytic anaemia through multi-immune modulation, induce a robust and sustained haemoglobin response, and provides an opportunity to decrease or stop corticosteroid use. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial Rilzabrutinib showed continued, stable, and sometimes improved platelet responses, including in patients who were initially non-responsive in the double-blind trial. Additionally, rilzabrutinib improved several disease aspects, including physical fatigue and bleeding, supporting its multi-immune modulation mechanism in immune thrombocytopenia, and had a favourable safety profile. The long-term extension period of LUNA3 will further characterise the long-term efficacy and safety of rilzabrutinib in patients with difficult-to-treat immune thrombocytopenia, and the ongoing LUNA4 trial (NCT07007962) will determine the efficacy of rilzabrutinib in earlier-line treatment and its potential to achieve sustained treatment-free response. Thu, 17 Sep 2026 22:30:01 +0000
[Articles] Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial Felzartamab plus lenalidomide–dexamethasone significantly prolonged progression-free survival compared with lenalidomide–dexamethasone alone, supporting felzartamab plus lenalidomide–dexamethasone as a potential new treatment option for Chinese patients with relapsed or refractory multiple myeloma. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial Topical ruxolitinib showed significant clinical activity and favourable harms profile in active cutaneous cGVHD. Ruxolitinib cream could represent a steroid-sparing, skin-directed alternative or second-line therapy, expanding treatment options for patients with cutaneous cGVHD. Wed, 16 Sep 2026 22:30:02 +0000
[Review] High time for risk-adapted treatment in mantle cell lymphoma Mantle cell lymphoma has multiple treatment options, yet the disease is difficult to cure. Relapses are common, treatments can cause severe side-effects, and current recommendations are still largely based on age rather than biology. Although suitability for intensive treatment was previously the decisive parameter, increasing knowledge on the biology of mantle cell lymphoma and less toxic targeted therapies has made non-risk adapted treatments outdated. TP53 mutations or deletions, blastoid histology, and a high Ki-67 proliferation index consistently identify patients at high risk of relapse. Wed, 02 Sep 2026 22:30:01 +0000
[Review] At the heart of unmet need: TP53 myeloid neoplasms TP53 myeloid neoplasms are being increasingly encountered in clinical practice and have been recognised in 2022, as a unique entity in the setting of functional loss of the two copies of the gene. The classification of myeloid neoplasm based on presence of biallelic (multi-hit) TP53 should precede morphological classification. The identification of biallelic (multi-hit) inactivation continues to evolve and is a matter of great debate balancing definitive biallelic identification via assays, pathology classifications, and clinical applicability. Thu, 01 Oct 2026 00:00:00 -0700
[Personal View] Redefining plasma cell leukaemia Plasma cell leukaemia is an aggressive plasma cell malignancy characterised by the presence of a high percentage of circulating clonal plasma cells on conventional peripheral blood smear examination. We argue that plasma cell leukaemia must no longer be considered as a separate disease entity but as a type of high-risk multiple myeloma. With the adoption of more strict criteria for defining high-risk multiple myeloma and the relaxation of criteria in defining plasma cell leukaemia, the clinical implications of the terms have converged. Fri, 21 Aug 2026 22:30:01 +0000
|
No cure without consequence: HCT and CH in SCD
Volume 148, Issue 17 October 22 2026 One CAR is good; are 2 CARs better? Volume 148, Issue 17 October 22 2026 Addressing CAR T-cell exhaustion through gene silencing Volume 148, Issue 17 October 22 2026 LIN28B: LINeage-dependent oncogene or tumor suppressor? Volume 148, Issue 17 October 22 2026 DEK: once a translocation partner, now an oncogenic effector Volume 148, Issue 17 October 22 2026 Age-related anemia: a new microbial clue in old blood Volume 148, Issue 17 October 22 2026 Reframing APS thrombogenesis: a new PF4-driven mechanism Volume 148, Issue 17 October 22 2026 Characteristics of donor and recipient clonal hematopoiesis in nonmyeloablative transplant for sickle cell disease Hematopoietic cell transplantation (HCT) offers a potentially curative therapy for sickle cell disease (SCD), but posttransplant complications, including clonal hematopoiesis (CH), may limit its long-term benefits. In a Plenary Paper, Weeks and colleagues identify newly emergent, donor-derived, and persistent recipient CH in a minority of patients after HCT, with TP53 mutations particularly associated with subsequent transplant-related myeloid neoplasms. These findings provide new insight into clonal evolution after HCT and the risks associated with HCT for SCD.
Volume 148, Issue 17 October 22 2026 How I treat autoimmune neutropenia in adults Autoimmune neutropenia (AiN) in adults is a rare, often chronic disorder with variable severity and poorly understood mechanisms of neutrophil destruction. In this How I Treat article, Leaf and Sykes explore the pathophysiology, diagnosis, and treatment of the disease through 4 illustrative cases. They underscore the need for an individualized approach and advocate for further research to better define disease mechanisms and develop more effective treatments.
Volume 148, Issue 17 October 22 2026 Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma Antigen loss is a major mechanism of relapse after B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, prompting various strategies to target multiple antigens. One is to administer 2 distinct products together. Mailankody and colleagues report the results of the Targeting Antigens with Novel Dual Effector cells for Multiple Myeloma (TANDEMM) phase 1 study, showing that concurrent administration of BCMA- and GPRC5D-directed CAR T cells is safe and can be effective in a heavily pretreated population. However, relapse in some patients through antigen loss and unequal CAR T-cell expansion indicates that dual targeting does not fully prevent resistance.
Volume 148, Issue 17 October 22 2026 Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial Chimeric antigen receptor (CAR) T-cell exhaustion limits the durability of responses in lymphoma, highlighting the need to preserve T-cell function during therapy. Kim et al attempted to achieve this by knocking down expression of 2 inhibitory receptors in a new CD19-directed CAR T-cell product. They report a 67% complete response rate in relapsed/refractory large B-cell lymphoma (LBCL) in a phase 1/2 trial of anbalcabtagene autoleucel, which uses gene silencing technology to reduce programmed death 1 (PD-1) and TIGIT expression. However, progression remains common, underscoring the need to determine whether targeting additional exhaustion pathways can improve long-term disease control.
Volume 148, Issue 17 October 22 2026 LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia Infant B-cell acute lymphoblastic leukemia (B-ALL) is driven by developmental programs that enable leukemic transformation of fetal hematopoietic cells. Ling and colleagues show that the fetal development–specific RNA-binding protein LIN28B is required for the initiation and maintenance of KMT2A::AFF1-positive infant B-ALL by promoting proliferation, B-cell differentiation, and cell survival. These findings identify LIN28B as a potential therapeutic target while highlighting its context- and lineage-dependent role in infant leukemia.
Volume 148, Issue 17 October 22 2026 Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming Casein kinase 2 (CK2) signaling contributes to acute myeloid leukemia (AML) stem cell maintenance, but the mechanisms linking this pathway to leukemic transformation remain undefined. Lei and colleagues show that CK2-dependent phosphorylation of DEK, an abundant nonhistone chromatin protein, promotes recruitment of the transcription factor GABPA to drive PBX3 expression, sustaining AML stemness, and demonstrate that pharmacological CK2 inhibition with CX-4945 synergizes with venetoclax to delay disease progression. These findings identify a CK2-DEK-GABPA-PBX3 pathway as a potential therapeutic vulnerability in AML.
Volume 148, Issue 17 October 22 2026 The gut microbiota drives aging-related erythropoiesis impairment via phenylacetic acid–induced histone phenylacetylation Anemia of aging is common, but its underlying mechanisms often remain unexplained despite standard diagnostic evaluation. Xie and colleagues identified an Odoribacter splanchnicus–phenylacetic acid pathway that impairs erythroid differentiation through histone phenylacetylation through disruption of the GATA switch required for normal erythroid maturation. These findings link aging-associated gut dysbiosis to impaired erythropoiesis and suggest potential microbiome- or metabolite-directed therapeutic strategies.
Volume 148, Issue 17 October 22 2026 Antiphospholipid syndrome is a platelet factor 4–centric immunothrombotic disorder Antiphospholipid syndrome (APS) is a thromboinflammatory disorder in which the mechanisms that drive severe thrombosis remain incompletely understood. Field and colleagues show that platelet factor 4 (PF4), a chemokine released from platelets, forms a large trimolecular complex with β2 glycoprotein I (β2GPI) and neutrophil extracellular traps that enhances anti-β2GPI antibody recognition and promotes platelet and neutrophil activation and thrombosis. These findings expand the traditional β2GPI-centered model of APS and identify PF4 as a potential therapeutic target.
Volume 148, Issue 17 October 22 2026 Kauskot A, Vandenbriele C, Louwette S, et al. PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway. Blood. 2013;121(26):5208-5217. Volume 148, Issue 17 October 22 2026 Chen L, Hu L, Liu X, et al. Single-cell profiling of ANKRD26 thrombocytopenia reveals progenitor expansion and polyploid apoptosis via JUNB-p21. Blood. 2026;147(17):1984-1998. Volume 148, Issue 17 October 22 2026 |
New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification
Fri, 23 Oct 2026 19:57:47 -0700 Heritability of Transcranial Doppler Velocity in Sickle Cell Anemia Across Two Independent Pediatric Cohorts Thu, 22 Oct 2026 19:39:34 -0700 Longevity in Thalassemia: Which Clock Are We Trying to Slow? Wed, 21 Oct 2026 18:30:30 -0700 Outcomes of Patients With AL Amyloidosis and End‐Stage Renal Disease After Initiation of Therapy Wed, 21 Oct 2026 07:34:46 -0700 Voxelotor in Children With Conditional Cerebral Blood Flow Velocity: What HOPE Kids 2 Teaches Us About Efficacy, Mortality, and Malaria Risk in Africa Tue, 20 Oct 2026 21:05:19 -0700 Utilization and Outcomes of Hemodialysis and Peritoneal Dialysis in Sickle Cell–Attributed End‐Stage Kidney Disease Mon, 19 Oct 2026 10:10:45 -0700 Rusfertide for Polycythemia Vera: Incremental Benefit Assessment Sat, 17 Oct 2026 04:58:57 -0700 A Novel Molecular Etiology of Paradoxical Hereditary Thrombocytosis Caused by Germline JAK2 Loss‐of‐Function Sat, 17 Oct 2026 03:38:20 -0700 Clarifying Transfusion Endpoint and Safety Reporting in the Phase III rhTPO Trial Fri, 16 Oct 2026 21:39:25 -0700 A Myeloma Masquerade: CCND3‐Rearranged Plasma Cell Myeloma Mimicking Lymphoplasmacytic Lymphoma Wed, 14 Oct 2026 21:15:06 -0700 Combination Therapy of Vinblastine, Prednisolone, Methotrexate, and 6‐Mercaptopurine as a Front‐Line Therapy for Adult Patients With Langerhans Cell Histiocytosis Wed, 14 Oct 2026 21:13:45 -0700 Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy Mon, 12 Oct 2026 21:04:54 -0700 Issue Information Mon, 12 Oct 2026 05:55:51 -0700 Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia Mon, 12 Oct 2026 05:55:51 -0700 Primary Plasma Cell Leukemia Mon, 12 Oct 2026 05:55:51 -0700 Myeloma Progression Without Osteolysis: Rethinking Whole‐Body Low‐Dose CT Criteria for Bone Disease Mon, 12 Oct 2026 05:55:51 -0700 Robustness of Hemophagocytic Lymphohistiocytosis Risk Estimates in CAR T‐Cell Therapy Mon, 12 Oct 2026 05:55:51 -0700 Hypomethylating Therapy in VEXAS Syndrome: Disease Modification Beyond Bridging to Transplant Mon, 12 Oct 2026 05:55:51 -0700 Hematopoietic Stem Cell Transplantation in Children With Transfusion Dependent β‐Thalassemia: A Two‐Decade Single‐Center Experience Mon, 12 Oct 2026 05:55:51 -0700 Cognitive Impairment, Depression and Cerebral Microbleeds in Immune Thrombocytopenia (ITP) Mon, 12 Oct 2026 05:55:51 -0700 Real‐World Outcomes of Venetoclax‐Based Therapy in Treatment‐Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study Mon, 12 Oct 2026 05:55:51 -0700 |
|
|
| |||
|
Thrombophilia testing: does it truly affect risk? October 13 2026 - Volume 10, Issue 19 Beyond hemolysis: redefining pediatric AIHA October 13 2026 - Volume 10, Issue 19 New views on VUSs in RUNX1-FPD October 13 2026 - Volume 10, Issue 19 Democratizing cancer risk testing in children before alloHCT October 13 2026 - Volume 10, Issue 19 CC-486 plus venetoclax: another step toward oral AML therapy October 13 2026 - Volume 10, Issue 19 The roots run deep in therapy-related myeloid neoplasms October 13 2026 - Volume 10, Issue 19 Of mice and FVIIIa mimetics: new hemophilia A models for in vivo evaluation October 13 2026 - Volume 10, Issue 19 CATCHing chronic GVHD October 13 2026 - Volume 10, Issue 19 Canadian emicizumab registry: a blueprint for the future October 13 2026 - Volume 10, Issue 19 HMA+VEN triplet regimens for the initial treatment of AML in adults (PRO) October 13 2026 - Volume 10, Issue 19 CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma October 13 2026 - Volume 10, Issue 19 HMA + venetoclax triplet regimens for the initial treatment of AML in adults October 13 2026 - Volume 10, Issue 19 Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma October 13 2026 - Volume 10, Issue 19 Venous thromboembolism is not associated with plasmin(ogen): reevaluating plasmin and mechanisms that degrade fibrin October 13 2026 - Volume 10, Issue 19 Burkitt lymphoma: current understanding, unmet needs, and research directions October 13 2026 - Volume 10, Issue 19 Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis October 13 2026 - Volume 10, Issue 19 MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL October 13 2026 - Volume 10, Issue 19 Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL October 13 2026 - Volume 10, Issue 19 Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis October 13 2026 - Volume 10, Issue 19 Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial October 13 2026 - Volume 10, Issue 19 Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia October 13 2026 - Volume 10, Issue 19 A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML October 13 2026 - Volume 10, Issue 19 A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia October 13 2026 - Volume 10, Issue 19 Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826) October 13 2026 - Volume 10, Issue 19 Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML October 13 2026 - Volume 10, Issue 19 Chronic GVHD consortium CATCH study: incidence, initial presentation, and risk factors for chronic GVHD development October 13 2026 - Volume 10, Issue 19 Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry October 13 2026 - Volume 10, Issue 19 Characterization of hematopoietic stem cell–derived microglia-like cells in nonhuman primates October 13 2026 - Volume 10, Issue 19 JARID2 inhibition reprograms human hematopoietic progenitor cells to enhance bone marrow transplantation October 13 2026 - Volume 10, Issue 19 HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL October 13 2026 - Volume 10, Issue 19 CD20 bispecific T-cell engager depletes B-cell progenitors preventing EBV-associated lymphomagenesis in humanized mice October 13 2026 - Volume 10, Issue 19 Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia October 13 2026 - Volume 10, Issue 19 Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial October 13 2026 - Volume 10, Issue 19 Genomic architecture of IRF4 rearrangements in childhood and adult large B-cell lymphomas October 13 2026 - Volume 10, Issue 19 Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma October 13 2026 - Volume 10, Issue 19 Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma October 13 2026 - Volume 10, Issue 19 Functional analysis of germline RUNX1 variants identified in individuals with suspected familial platelet disorder October 13 2026 - Volume 10, Issue 19 Comutation of asxl1 and IDH2R172K enhances leukemogenesis and correlates with epigenetic activation of MAPK and AP-1 in zebrafish October 13 2026 - Volume 10, Issue 19 Germ line landscape stratification defines distinct molecular and prognostic groups in therapy-related myeloid neoplasms October 13 2026 - Volume 10, Issue 19 Real-world investigation of germ line predisposition to myelodysplastic syndromes October 13 2026 - Volume 10, Issue 19 Rapid and reproducible karyotyping with long-read sequencing in patients with AML October 13 2026 - Volume 10, Issue 19 A prospective study of familial predisposition to plasma cell dyscrasias October 13 2026 - Volume 10, Issue 19 Predictors of posttransplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma October 13 2026 - Volume 10, Issue 19 Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations October 13 2026 - Volume 10, Issue 19 Pediatric autoimmune hemolytic anemia is associated with a high incidence of underlying immune disorders October 13 2026 - Volume 10, Issue 19 Characterization of a mouse model to study mechanisms of hemophilia A pain October 13 2026 - Volume 10, Issue 19 Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP October 13 2026 - Volume 10, Issue 19 Tenecteplase and other TNK formulations lose PAI-1 resistance in their 2-chain form: comparison with alteplase October 13 2026 - Volume 10, Issue 19 A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies October 13 2026 - Volume 10, Issue 19 Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States October 13 2026 - Volume 10, Issue 19 In vivo and ex vivo impact of THBD and PROCR polymorphisms on the anticoagulant response of the protein C pathway October 13 2026 - Volume 10, Issue 19 Outcomes of germ line testing for children with hematologic malignancies undergoing hematopoietic cell transplantation October 13 2026 - Volume 10, Issue 19 Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis October 13 2026 - Volume 10, Issue 19 Frequency, kinetics, and clinical significance of HHV-6 DNAemia after PTCy-based hematopoietic cell transplant October 13 2026 - Volume 10, Issue 19 Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights October 13 2026 - Volume 10, Issue 19 Hydroxyurea reduces hyperadhesion measured by a VLA-4–targeting PET tracer in sickle transgenic Townes mice October 13 2026 - Volume 10, Issue 19 Donor-targeted anti–HLA-A2 antibody shows nanogram-level efficacy in a novel GVHD mouse model October 13 2026 - Volume 10, Issue 19 Are statins interferon’s best friends? Mechanistic insights October 13 2026 - Volume 10, Issue 19 Potential mechanisms of statin and interferon-α2 therapy October 13 2026 - Volume 10, Issue 19 Yu H, Schroeder JA, Mattson JG, Gao C, and Shi Q. Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice. Blood Adv. 2026;10(6):1883-1896. October 13 2026 - Volume 10, Issue 19 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Ianalumab for the Treatment of Patients with Sjögren’s Disease
New England Journal of Medicine, Volume 395, Issue 16, Page 1585-1599, October 22, 2026.
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy New England Journal of Medicine, Volume 395, Issue 16, Page 1610-1620, October 22, 2026.
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event New England Journal of Medicine, Volume 395, Issue 16, Page 1575-1584, October 22, 2026.
Reengineering Coagulation with a Bispecific Antibody New England Journal of Medicine, Volume 395, Issue 16, Page 1649-1652, October 22, 2026.
IVUS-Guided PCI in Left Main Coronary Disease New England Journal of Medicine, Volume 395, Issue 16, Page 1662-1665, October 22, 2026.
Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer New England Journal of Medicine, Volume 395, Issue 16, Page 1661-1662, October 22, 2026.
In Vivo Aquaporin-1 Circular RNA Therapy for Radiation-Induced Xerostomia New England Journal of Medicine, Volume 395, Issue 16, Page 1659-1661, October 22, 2026.
Ianalumab in Sjögren’s Disease — A First Step New England Journal of Medicine, Volume 395, Issue 16, Page 1644-1646, October 22, 2026.
Infective Endocarditis — When Is Enough Enough? New England Journal of Medicine, Volume 395, Issue 16, Page 1647-1648, October 22, 2026.
Spinal Tuberculosis New England Journal of Medicine, Volume 395, Issue 16, Page 1634-1634, October 22, 2026.
Examining the Use of Race in Clinical Algorithms New England Journal of Medicine, Volume 395, Issue 16, October 22, 2026.
Why Shared-Savings ACOs Have Failed to Deliver for Primary Care New England Journal of Medicine, Volume 395, Issue 16, Page 1567-1570, October 22, 2026.
Clinical Trial Prediction Markets — Information, at What Cost? New England Journal of Medicine, Volume 395, Issue 16, Page 1565-1567, October 22, 2026.
Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism New England Journal of Medicine, Ahead of Print.
Eplontersen for Transthyretin Amyloid Cardiomyopathy New England Journal of Medicine, Ahead of Print.
Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension New England Journal of Medicine, Ahead of Print.
Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain New England Journal of Medicine, Ahead of Print.
Tozorakimab to Prevent COPD Exacerbations New England Journal of Medicine, Ahead of Print.
Short or Long Antibiotic Regimens in Orthopedics New England Journal of Medicine, Ahead of Print.
Immediate Ambulatory Electrocardiographic Monitoring in Syncope New England Journal of Medicine, Ahead of Print.
Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea New England Journal of Medicine, Ahead of Print.
Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis New England Journal of Medicine, Ahead of Print.
Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy New England Journal of Medicine, Ahead of Print.
Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic Stroke New England Journal of Medicine, Ahead of Print.
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC New England Journal of Medicine, Ahead of Print.
Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer New England Journal of Medicine, Ahead of Print.
In Vitro Fertilization or Intrauterine Insemination in Unexplained Infertility New England Journal of Medicine, Ahead of Print.
Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury New England Journal of Medicine, Ahead of Print.
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer New England Journal of Medicine, Ahead of Print.
Expanding the Evidence and Indications for Thrombectomy in Ischemic Stroke New England Journal of Medicine, Ahead of Print.
Thelaziasis New England Journal of Medicine, Ahead of Print.
The Future of Health Agency Enforcement Fines New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
About the cover image
Issue Highlights Whither Proton Therapy? Whither Particles? Proton Therapy for Breast, Prostate, and Leptomeningeal Disease—Some Answers, but Questions Persist Pros for Protons: When, Where, and How Much? Protons Without a Proton Centre: A Canadian Perspective on Oropharyngeal Cancer Treated With Photons In Oropharynx Cancer, Protons or Photons Will Do the Job Morbidity Depends More on Volume and Dose Than on Particle Intensity Modulated Proton Therapy for Oropharyngeal Cancer Technical Considerations on Proton Therapy in NRG’s Multi-Institutional Clinical Trials Expanding Particle Beam Therapy in Asia-Oceania: Model to Improve Access Assessing the Economic Feasibility and Social Impact of Proton Therapy: Implementation in Mexico and Latin America Characteristics of Crowdfunding Campaigns for Proton Therapy Initiating Proton Ocular Treatments on General-Purpose Beamlines: Challenges and Trends From the Survey of US Facilities Multivariable Normal Tissue Complication Probability Prediction of Early Grade Radiation-Induced Optic Neuropathy Using Visual Field Deficit in a Prospective Pencil Bean Scanning Proton Therapy Cohort International Consensus Guidelines for Radiation Target Volume Delineation for Skull Base Chordoma—A Particle Therapy Co-operative Group Initiative Multimodel RBE and Dose-Averaged LET Optimized Carbon Ion Radiation Therapy for Sacral Chordoma: Results of the First Year of Clinical Application Carbon Ion Radiation Therapy of Sacrococcygeal Chordomas: A Comparison of Different Fractionation Schemes Local Control and Outcomes Associated With Proton Spine Hypofractionated Radiation Therapy The Evolution of Radiation Therapy in Children’s Oncology Group Trials, From 1998 to 2025 Memantine for Prevention of Cognitive Late Effects in Children and Adolescents Receiving Radiation Therapy for Brain Tumors: A Randomized, Controlled, Pilot Trial Voxel-Wise Case-Control Analysis of Dose, Linear Energy Transfer, and Symptomatic Brainstem Necrosis in Pediatric Brain Tumors Treated With Proton Therapy Total-Body PET/CT Imaging After Proton Craniospinal Irradiation in Pediatric Patients: A Brief Report Deep Learning Blood Dosimetry Predicts Severe Lymphopenia and Survival After Craniospinal Irradiation Proton Beam Therapy in Nonmetastatic Rhabdomyosarcoma: Outcome, Prognostic Factors, and the Effect of Timing of Radiation Therapy Proton Radiotherapy Offers Immune-Sparing Benefits in Glioblastoma Treatment Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single-Institution Series Patient-Reported Outcomes, Neurocognitive Functioning, and Oncologic Results of Pencil Beam Scanning Proton Beam Therapy for CNS WHO G2 and G3 IDH1-Mutant Diffuse Adult Glioma: A Single Institution Experience Radiation-Induced Alopecia in Patients Undergoing Intracranial Radiation Therapy: A Systematic Review Proton Therapy in Nasopharyngeal Carcinoma: An Outlier in Head and Neck Cancer? Association Between Linear Energy Transfer Distribution and Local Recurrence in Recurrent Nasopharyngeal Carcinoma Reirradiated With Intensity-Modulated Carbon Ion Therapy Qualitative Blinded Clinical Assessment of Automated and Manual IMPT Plans for Head and Neck Cancer A Learning-Driven Automatic Planning Framework for Proton Pencil Beam Scanning Treatments of Head and Neck Cancers Proton Radiation for Locally Advanced Breast Cancer: Evolution and Techniques Associations Between Cardiac Radiation Dose-Volume Metrics and Health-Related Quality of Life for Patients With Breast Cancer on the RadComp Trial Acute Radiation Side Effects of Proton Versus Photon Therapy Following Surgery for Early Breast Cancer, a Substudy of the Randomized Controlled Danish Breast Cancer Group Proton Trial Comparative Analysis of Acute Skin Reactions After Postmastectomy Photon and Intensity Modulated Proton Therapy Dose-Linear Energy Transfer Interactions Predict Capsular Contracture After Proton Postmastectomy Radiation Therapy Does Pencil Beam Scanning Proton Therapy Impart a Higher Risk of Capsular Contracture Compared With Intensity Modulated Photon Radiation Therapy in the Postmastectomy Reconstruction Setting? Radiobiological and Treatment Planning Evidence Supporting Particle Therapy in Aggressive Breast Cancer Long-Term Outcomes After Proton Therapy Versus Intensity Modulated Photon Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Post Hoc Analysis of a Prospective Randomized Trial Comparing Strategies for Pencil Beam Scanning Carbon Ion Radiation Therapy in Stage I Peripheral Non-Small Cell Lung Cancer: Toward Optimized Clinical Decision-Making Planning A Gaussian-Based Planning Approach for Robust Dose-Escalated Stereotactic Body Proton Therapy Proton Therapy for Hemithoracic Pleural Irradiation: A Step Toward Safer Radiation Treatment Predicting End-of-Treatment Ventilation Response to Radiation Therapy Using Early Treatment Ventilation for Patients With Lung Cancer Treated With Photons and Protons Proton Beam Therapy for Large Localized Hepatocellular Carcinomas in Western Patients Liver Tumor Motion and Reconstructed Doses in a Clinical Trial of Respiratory-Gated Proton Therapy for Hepatocellular Carcinoma Gastrointestinal Motility-Induced Interplay in Pancreas Proton Therapy: Motion Simulation and Dosimetric Impact Less Dose, More Immunity? Reframing Proton Therapy for Cervical Cancer in the Pembrolizumab Era |
A Penny for Your Thoughts October 2026: 69(10):2399-2401 Ventral Mesh Rectopexy and Rectal Cancer: An Underrecognized Concern October 2026: 69(10):2402-2403 Artificial Intelligence for Colorectal Surgeons—Part II: Research Applications, Challenges in Adoption, and Practical Resources October 2026: 69(10):2404-2412 What Every Colorectal Surgeon Should Know About Private Equity in Ambulatory Practices: Structure, Practice Models, and Implications for Physicians October 2026: 69(10):2413-2417 Compliance With the American Society of Colon and Rectal Surgeons Preoperative Checklist in Rectal Cancer Care in Ghana: Gaps and Opportunities for Improvement—A Cross-Sectional Study October 2026: 69(10):2418-2424 Management and Survivorship Considerations in Early-Onset Rectal Cancer October 2026: 69(10):2425-2428 Expert Commentary on Management and Survivorship Considerations in Early-Onset Rectal Cancer October 2026: 69(10):2429-2430 The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Left-Sided Colonic Diverticulitis October 2026: 69(10):2431-2450 Lymph Node Harvest and Prognosis in Stage II and III Rectal Cancer in the Era of Total Neoadjuvant Therapy October 2026: 69(10):2451-2461 Outcomes and Molecular Correlates of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases October 2026: 69(10):2462-2472 Three-Year Follow-up of the Randomized Trial Comparing Open Versus Laparoscopic Surgery for Primary Tumor Resection in Patients With Noncurable Stage IV Colon Cancer (JCOG1107) October 2026: 69(10):2473-2483 Five-Year Follow-up of the Double-Blinded Randomized Controlled Trial Comparing Laser Hemorrhoidoplasty With Sutured Mucopexy and Excisional Hemorrhoidectomy October 2026: 69(10):2484-2491 Patterns and Outcomes of Elective Versus Nonelective Rectal Prolapse Repair: An American College of Surgeons National Quality Surgical Improvement Program Analysis October 2026: 69(10):2492-2499 Short- and Long-term Outcomes of 3-Row Vs 2-Row Circular Staplers for Low Colorectal Anastomosis After Total Mesorectal Excision: A Single-Center, Randomized, Single-Blind, Phase III Trial (THREESTAPLER Study) October 2026: 69(10):2500-2510 Clinical and Physiological Characterization of Neurogenic Bowel Dysfunction in Motor-Incomplete Spinal Cord Injury October 2026: 69(10):2511-2520 Computer Vision Approach to Triaging Patient-Submitted Photos of Intestinal Ostomies October 2026: 69(10):2521-2530 Selected Abstracts October 2026: 69(10):2531-2534 Single Incision Plus One Robot-Assisted Surgery for Right-Sided Colon Cancer October 2026: 69(10):2535-2535 Video Demonstration of Single-Port Robotic Transanal Total Mesorectal Excision Using Newly Developed Surgical Robot System October 2026: 69(10):2536-2537 Mastering the Planes: Laparoscopic Left Hemicolectomy With Complete Mesocolic Excision October 2026: 69(10):2538-2539 |
||
|
| |||
|
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
The final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides and Sézary syndrome were recently presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany... Thursday, October 22, 2026 12:45 PM FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors On October 16, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high... Thursday, October 22, 2026 4:30 PM Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials A recent study by researchers from The Univetsity of Texas MD Anderson Cancer Center, ASCO, and collaborating institutions evaluated the national landscape of geographic access to active triple-negative breast cancer clinical trials. The findings—published by Amin et al in Breast Cancer Research... Thursday, October 22, 2026 11:39 AM Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening Among medically underserved adults who smoked and were referred for lung cancer screening, the addition of financial incentives to usual care and free pharmacotherapy significantly increased rates of sustained tobacco abstinence compared with usual care alone or usual care plus free... Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer The addition of metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic breast cancer, according to findings from the randomized phase II portion of the NRG-BR002 trial reported by Chmura et al... Claudia Henschke, PhD, MD: Finding Lung Cancer in Time I have had many idols in medicine. Many eventually let me down. Remote Expert Case Reviews Identify Opportunities to Improve Cancer Care and Reduce Costs Remote expert review of oncology cases may help to address and improve gaps in evidence-based cancer care, while also providing measurable cost savings, according to findings presented in a poster at the 2026 ASCO Quality Care Symposium (Abstract 700). Wednesday, October 21, 2026 1:00 PM Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction A shorter course of postmastectomy radiation therapy was noninferior to conventional radiation therapy in terms of breast reconstruction complications among women with breast cancer undergoing the procedure, according to findings from the randomized RT CHARM trial reported by Poppe et al in the Experts Call for Better Quality-of-Life Reporting in Adjuvant Cancer Trials Clinical trials of adjuvant cancer therapy should do a better job of showing how treatment affects individual patients’ quality of life—particularly when the survival benefit is modest—according to recommendations from Common-Sense Oncology and the European Organisation for Research and Treatment... Starting Surveillance Colonoscopy After High-Risk Adenoma Removal: When Is the Right Time? Surveillance colonoscopy at 5 years after removal of high-risk adenomas was noninferior to surveillance at 3 years in terms of colorectal cancer incidence during the first 5 years after adenoma removal, according to an interim analysis of the randomized EPoS II trial reported by Jover et al in The... AI Model Based on Facial Image Analysis Estimates Biological Age and Mortality Risk in Patients With Cancer Analyzing facial images using a foundational artificial intelligence (AI) model may help researchers determine both biological aging and disease-related mortality risk, according to study findings published in The Lancet Digital Health. Tuesday, October 20, 2026 1:30 PM Community Oncology Practices Bring Advances in Cancer Testing and Treatment Closer to Patients Community oncology practices are bringing personalized medicine into everyday cancer care, substantially expanding their use of advanced biomarker testing and novel therapies for patients with metastatic breast cancer and metastatic non–small cell lung cancer, according to new research from... Tuesday, October 20, 2026 10:55 AM FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer On October 8, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients aged 2 years and older with stage III mismatch repair–deficient (dMMR) colon cancer. The FDA... Friday, October 9, 2026 10:38 AM FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer On October 19, 2026, the U.S. Food and Drug Administration (FDA) granted an accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) for the treatment of adult patients with stage II/III locally advanced rectal cancer that is microsatellite instability–high (MSI-H) or mismatch repair... Monday, October 19, 2026 3:00 PM National Academy of Medicine Elects 100 New Members for 2026 The National Academy of Medicine (NAM) has announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated... Monday, October 19, 2026 3:06 PM Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera According to findings from the phase III VERIFY trial reported by Kuykendall et al in the Journal of Clinical Oncology, the addition of the hepcidin mimetic rusfertide to standard-of-care therapy significantly improved hematocrit control, reduced the need for phlebotomy, and improved... ASH Issues New Recommendations for the Management of Myelofibrosis The American Society of Hematology (ASH) released new guidelines on the management of myelofibrosis which recommend expanded molecular testing, early transplant referral, appropriate use of JAK inhibitors, and aspirin therapy in select patients. The guidelines were published by Stein et al in Blood ... Monday, October 19, 2026 10:28 AM Immunotherapy-Based Downstaging Linked to Improved Outcomes After Liver Transplantation in Hepatocellular Carcinoma An immune checkpoint inhibitor–based multimodal downstaging strategy before liver transplantation was associated with improved posttransplant survival and a lower risk of recurrence among patients with hepatocellular carcinoma initially beyond the Milan criteria (single lesion not larger than 5 cm... Novel Androgen Receptor Degrader Demonstrates Antitumor Activity in Advanced Prostate Cancer The novel androgen receptor degrader bavdegalutamide demonstrated a manageable safety profile and antitumor activity in patients with metastatic castration–resistant prostate cancer previously treated with androgen receptor pathway inhibitors, particularly those with tumors harboring specific... Verifying the Seen and Unseen by AI in Cancer Imaging Artificial intelligence (AI) can be used in medical imaging and diagnostics to enhance physician capabilities, but also to identify features that humans are not able to see. In research settings, AI has already demonstrated that ability to identify biomarkers from routine medical images and guide... AI-Extracted Chart Data for Expanding Surgical Oncology Learnings Large language models (LLMs) are capable of extracting structured data directly from electronic medical records, expanding data sets available for research, training, and developing artificial intelligence (AI) models. Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families, Study Finds New research published by Rodwin et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that families of children receiving treatment for B-cell acute lymphoblastic leukemia (ALL) experience substantial and lasting challenges beginning early after diagnosis, according to a... Friday, October 16, 2026 11:04 AM Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas Survival and mortality disparities for women with breast cancer are widening between rural and urban areas over time, according to findings from two American Cancer Society studies presented at the 2026 ASCO Quality Care Symposium (Abstracts 208 and 253). Thursday, October 15, 2026 4:39 PM FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved the IL-15 receptor agonist nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). Wednesday, October 14, 2026 12:45 PM Iberdomide Triplet Improves MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma Iberdomide combined with daratumumab and dexamethasone nearly doubled the rate of minimal residual disease (MRD)-negative complete response compared with daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. Lonial et al reported the primary MRD... Study Supports Sentinel Lymph Node Biopsy After Chemotherapy in Locally Advanced Breast Cancer A prospective study found that sentinel lymph node biopsy may be an accurate method of axillary staging in selected patients with locally advanced breast cancer who achieve a clinical nodal response to neoadjuvant chemotherapy—potentially allowing some patients to avoid axillary lymph node... |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
No cancer research without older adults, from prevention to end of life: a manifesto
Older adults (aged ≥65 years) comprise the majority of people diagnosed with cancer, yet they remain proportionally underrepresented in cancer research at every stage of the pathway. We call on funders, regulators, researchers and journals to make systematic inclusion of older adults the norm, across studies spanning from cancer prevention to end-of-life care. Tue, 20 Oct 2026 00:00:00 -0700 An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval The FDA recently approved daraxonrasib for patients with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Critics call the second clause non-evidence based. However, this imprecision enables access: trials generally enrol only patients with good performance status, which does not reflect the realities for most patients with metastatic pancreatic adenocarcinoma who never reach second-line therapy because their clinical condition deteriorates first. Real-world evidence should resolve any remaining uncertainty. Tue, 13 Oct 2026 00:00:00 -0700 A modular framework for antibody–drug conjugate biomarkers Antibody–drug conjugates (ADCs) have transformed the management of various advanced-stage solid cancers. Nonetheless, and despite considerable development efforts, many of these agents lack reliable biomarkers of clinical benefit and/or are reliant on traditional methods of biomarker assessment, with biomarkers of resistance and/or toxicity largely overlooked. In this Review, the authors outline a modular ADC biomarker development strategy that considers the various components of these agents and discuss how biomarkers developed using this strategy might better inform patient selection, therapeutic sequencing, the development of rational combinations, dose optimization and regulatory strategy. Fri, 09 Oct 2026 00:00:00 -0700 Adjuvant radiotherapy improves outcomes in patients with completely resected atypical meningioma Adjuvant radiotherapy improves outcomes in patients with completely resected atypical meningioma Thu, 08 Oct 2026 00:00:00 -0700 Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum The iterative development of several highly effective treatments for HER2-positive breast cancer has transformed patient outcomes, but the now-crowded therapeutic landscape raises questions regarding the optimal approach for each patient. In this Review, the authors outline considerations for right-sizing therapy across the disease continuum, and discuss biomarkers that might facilitate this more individualized approach to treatment. Thu, 08 Oct 2026 00:00:00 -0700 Exercise therapy in cancer prevention and treatment Exercise is widely endorsed as a supportive-care adjunct to mitigate adverse effects of cancer treatment, with data also suggesting potential therapeutic and preventive roles. In this Review, the authors discuss the current evidence from epidemiological studies and clinical trials for exercise as a factor modulating primary cancer risk and disease outcomes after diagnosis, and describe a translational framework for continued development of exercise therapy and a path towards precision exercise oncology. Wed, 07 Oct 2026 00:00:00 -0700 Exploring the immunological effects of antibody–drug conjugates Antibody–drug conjugates (ADCs) have reshaped the therapeutic landscape of many advanced-stage cancers. This clinical activity probably reflects mechanisms beyond targeted cytotoxicity, with emerging evidence suggesting an immune-mediated component. At the same time, regimens combining ADCs with immune checkpoint inhibitors (ICIs) are emerging as a highly effective treatment strategy in various malignancies. In this Review, the authors discuss the immunological mechanisms of action of ADCs, their clinical activity in combination with ICIs, as well as the potential of future agents and regimens to further improve outcomes. Tue, 06 Oct 2026 00:00:00 -0700 Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL Thu, 01 Oct 2026 00:00:00 -0700 |
|
|
| |||
|
Genomic alterations associated with response to neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
Vol 17, No 5 (October 30, 2026): CDC73 suppresses migration, proliferation, and apoptosis resistance in esophageal squamous cell carcinoma via the JNK/p38/ERK MAPK pathway Vol 17, No 5 (October 30, 2026): Incidence and pathology-based predictive modeling of lymph node metastasis in early gastric cancer: evidence from a retrospective single-center Chinese surgical cohort with internal validation Vol 17, No 5 (October 30, 2026): Diagnostic performance of contrast-enhanced transabdominal ultrasound with gastric filling in preoperative T-staging of advanced gastric cancer: a retrospective study Vol 17, No 5 (October 30, 2026): Clinicopathological comparison of gastric cancer in young (<45 years) versus elderly (>60 years) patients: a single-center retrospective study Vol 17, No 5 (October 30, 2026): Prehabilitation and postoperative outcomes in gastric cancer surgery: a systematic review and meta-analysis Vol 17, No 5 (October 30, 2026): Operative efficiency and perioperative safety of overlap versus π-shaped esophagojejunostomy after totally laparoscopic total gastrectomy for gastric cancer: a systematic review and meta-analysis Vol 17, No 5 (October 30, 2026): Feasibility of a standardized pathological protocol for lymphatic basin evaluation during sentinel node navigation surgery in early gastric cancer: preliminary results from the FLECSS trial Vol 17, No 5 (October 30, 2026): Neoadjuvant therapy-related skeletal muscle reduction and postoperative outcomes after gastrectomy for gastric cancer: a systematic review and meta-analysis Vol 17, No 5 (October 30, 2026): Impact of tumor grade and tumor stage on cardiovascular death in colorectal cancer patients with chemotherapy or radiotherapy: a retrospective cohort study Vol 17, No 5 (October 30, 2026): Development and temporal validation of a pathology-based model incorporating the lymph node ratio to predict recurrence in stage III colorectal cancer Vol 17, No 5 (October 30, 2026): An immunogenic cell death-related classification for prognostic stratification and immunotherapy response prediction in proficient mismatch repair/microsatellite stable colorectal cancer Vol 17, No 5 (October 30, 2026): FAM84B drives colon adenocarcinoma progression via stemness maintenance and tumor microenvironment remodeling Vol 17, No 5 (October 30, 2026): A phase II pilot evaluation of lurbinectedin in patients with advanced gastrointestinal malignancies with DNA repair mutations Vol 17, No 5 (October 30, 2026): ANGPT2 promotes angiogenesis and immunosuppressive microenvironment in colorectal cancer Vol 17, No 5 (October 30, 2026): Development and internal validation of a clinical-MRI nomogram for predicting lymph node metastasis in rectal adenocarcinoma Vol 17, No 5 (October 30, 2026): Comparing the efficacy and safety of raltitrexed combined with irinotecan administered in different dose-schedule patterns for the second-line treatment of metastatic colorectal cancer: an exploratory, observational post hoc analysis from the prospective SALLY registry cohort Vol 17, No 5 (October 30, 2026): Development and external validation of an explainable machine learning model using routine perioperative clinical variables for postoperative pulmonary complication risk stratification after hepatectomy for primary liver cancer Vol 17, No 5 (October 30, 2026): Treatment completion, symptom response, and survival after palliative liver-directed radiotherapy: a retrospective cohort study Vol 17, No 5 (October 30, 2026): Early on-treatment alpha-fetoprotein and des-gamma-carboxy prothrombin responses are associated with outcomes in unresectable hepatocellular carcinoma receiving transarterial chemoembolization, tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors Vol 17, No 5 (October 30, 2026): Pre-transplant locoregional therapy and post-transplant outcomes in hepatocellular carcinoma: a single-center retrospective cohort study Vol 17, No 5 (October 30, 2026): Primary tumor surgery in AJCC eighth edition stage I intrahepatic cholangiocarcinoma: real-world treatment patterns, SEER-recorded reasons for nonreceipt, and associated survival outcomes Vol 17, No 5 (October 30, 2026): Clinical outcomes of hepatitis B virus-related versus non-B non-C hepatocellular carcinoma treated with transarterial chemoembolization, tyrosine kinase inhibitors, and PD-1 inhibitors: a retrospective cohort study Vol 17, No 5 (October 30, 2026): Self-expandable metal stent (SEMS) with iodine-125 intraluminal brachytherapy versus SEMS alone for unresectable malignant distal biliary obstruction: survival and patency analysis Vol 17, No 5 (October 30, 2026): Hepatic arterial infusion chemotherapy in combination with immune checkpoint inhibitors and targeted therapy for advanced intrahepatic cholangiocarcinoma Vol 17, No 5 (October 30, 2026): Subtypes of invasive intracholecystic papillary-tubular neoplasms: a propensity score-matched Surveillance, Epidemiology, and End Results analysis Vol 17, No 5 (October 30, 2026): Preoperative prediction of microvascular invasion in hepatocellular carcinoma using routine clinical variables: development and temporal validation of an interpretable random forest model in a single-center retrospective cohort study Vol 17, No 5 (October 30, 2026): Development and internal validation of a pretreatment magnetic resonance imaging-based radiomics prediction model for 1-year overall survival in treatment-naïve patients with hepatocellular carcinoma receiving transarterial chemoembolization combined with targeted therapy and immune checkpoint inhibitors Vol 17, No 5 (October 30, 2026): MTA1 promotes hepatocellular carcinoma progression by remodeling the immune microenvironment and regulating drug resistance gene networks: an integrated multi-database analysis Vol 17, No 5 (October 30, 2026): Reassessing standard neoadjuvant gemcitabine plus S-1 for resectable pancreatic head cancer: a retrospective cohort study Vol 17, No 5 (October 30, 2026): Association between white blood cell-to-hemoglobin ratio and in-hospital mortality among critically ill patients with pancreatic cancer: a retrospective cohort study based on MIMIC-IV and eICU-CRD Vol 17, No 5 (October 30, 2026): Development and preliminary clinical characterization of an MDT-defined surgical-window framework for complex pancreatic cancer: a retrospective cohort study Vol 17, No 5 (October 30, 2026): Dual-energy computed tomography as an alternative to computed tomography perfusion for assessment of pancreatic ductal adenocarcinoma Vol 17, No 5 (October 30, 2026): Treatment strategies in pancreatic adenosquamous carcinoma: a systematic review and pooled analysis of individual cases Vol 17, No 5 (October 30, 2026): Breakdown analysis of the cost development of pancreatic surgery after centralization Vol 17, No 5 (October 30, 2026): Prognostic and predictive biomarkers in colorectal cancer: from established molecular markers to Mediator complex-related transcriptional reprogramming—a narrative review Vol 17, No 5 (October 30, 2026): The gut microbiota across the colorectal cancer surgical continuum—a narrative review Vol 17, No 5 (October 30, 2026): Adjuvant immunotherapy after curative-intent treatment for hepatocellular carcinoma: evidence, limitations, and a research framework for molecular residual disease-guided intervention—a narrative review Vol 17, No 5 (October 30, 2026): Current imaging methods and molecular biomarkers for hepatocellular carcinoma diagnosis: a narrative review Vol 17, No 5 (October 30, 2026): Clinical applications and recent advances in multimodal image fusion for hepatocellular carcinoma diagnosis: a narrative review Vol 17, No 5 (October 30, 2026): Engineered bacteria-mediated stromal remodeling in pancreatic ductal adenocarcinoma: therapeutic opportunities and translational limits—a narrative review Vol 17, No 5 (October 30, 2026): Management of diarrhea in patients receiving liposomal irinotecan-based regimens: a narrative review of mechanisms, clinical impact, and evidence-based strategies Vol 17, No 5 (October 30, 2026): Neoadjuvant transarterial chemoembolization, camrelizumab, and apatinib for centrally located hepatocellular carcinoma (NEO-CENTACT): study protocol for a phase II trial Vol 17, No 5 (October 30, 2026): Metastatic pulmonary ETV6::NTRK3 mucinous adenocarcinoma originating from an intraductal papillary mucinous neoplasm case report Vol 17, No 5 (October 30, 2026): Trastuzumab rezetecan (SHR-A1811) for the treatment of HER2-positive advanced colorectal cancer: a report of two cases Vol 17, No 5 (October 30, 2026): Diagnostic approaches for neuroendocrine tumors of unknown primary: the role of surgical exploration and advances in molecular profiling Vol 17, No 5 (October 30, 2026): Beyond liver and bone: what Lauren classification, metastatic organotropism, and Surveillance, Epidemiology, and End Results can and cannot tell us about metastatic gastric cancer Vol 17, No 5 (October 30, 2026): Husky or lean and everything in between: the double-edged prognostic role of body mass index in pancreatic cancer Vol 17, No 5 (October 30, 2026): Earlier colorectal cancer or earlier recognition of inherited risk? Interpreting age shifts in hereditary cancer cohorts Vol 17, No 5 (October 30, 2026): Can pyruvate kinase M2 identify who benefits from adjuvant oxaliplatin in colorectal cancer? Vol 17, No 5 (October 30, 2026): RNA-based gene fusion testing for gastrointestinal malignancies Vol 17, No 5 (October 30, 2026): Nursing coordination in enhanced recovery after colorectal cancer surgery: from bundled care to accountable implementation Vol 17, No 5 (October 30, 2026): Translating fibroblast heterogeneity into prognosis and immune stratification in pancreatic cancer using machine learning Vol 17, No 5 (October 30, 2026): Beyond five years: redefining survivorship after gastrectomy for gastric cancer Vol 17, No 5 (October 30, 2026): Tumor deposits in stage III colorectal cancer: time for the TNM system to catch up Vol 17, No 5 (October 30, 2026): Revisiting alpha-fetoprotein thresholds for hepatocellular carcinoma surveillance in the metabolic dysfunction-associated steatotic liver disease era: time for an evidence-based recalibration Vol 17, No 5 (October 30, 2026): Tinengotinib, an arising option for FGFR inhibitor resistant cholangiocarcinoma Vol 17, No 5 (October 30, 2026): Reflections on p62/SQSTM1-mediated NF-κB activation and PD-L1 induction in gastric cancer immune evasion Vol 17, No 5 (October 30, 2026): Erratum: MS4A3 as a potential prognostic biomarker for colon cancer: integrated analysis of expression patterns and immune cell infiltration Vol 17, No 5 (October 30, 2026): |
|
||
|
| |||
|
Economic Impact of the 2025 New Mexico Measles Outbreak: Highlighting the Cost of Efforts to Prevent Future Outbreaks
Annals of Internal Medicine, Volume 179, Issue 10, Page 1369-1374, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Longitudinal Changes in Heart Stress and the Risk for Cardiovascular Disease and Mortality in Older Adults Annals of Internal Medicine, Volume 179, Issue 10, Page 1375-1385, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Periconception Parental Red Blood Cell Folate, Vitamin B12, and Birth Defects in Offspring Annals of Internal Medicine, Volume 179, Issue 10, Page 1386-1397, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Association Between Blood Hemoglobin Concentration and Mortality by Age and Sex Annals of Internal Medicine, Volume 179, Issue 10, Page 1398-1411, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes Annals of Internal Medicine, Volume 179, Issue 10, Page 1412-1429, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Interventions to Improve Outpatient Follow-up for Hospitalized Patients With Alcohol Use Disorder Annals of Internal Medicine, Volume 179, Issue 10, Page 1430-1443, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Randomized Quality Improvement Trials: An Overview and Proposed Framework for Ethical Oversight Annals of Internal Medicine, Volume 179, Issue 10, Page 1444-1452, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction Annals of Internal Medicine, Volume 179, Issue 10, Page 1460-1472, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 How Would You Screen This 26-Year-Old Woman for Cervical Cancer? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 179, Issue 10, Page 1473-1481, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Ethics and Professionalism in Artificial Intelligence and Medical Practice: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 10, Page 1453-1459, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 International Medical Graduates in America: Navigating a Winding History of Immigration Laws and Licensure Requirements Annals of Internal Medicine, Volume 179, Issue 10, Page 1482-1488, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Infection Surveillance at 50: Are We Still Measuring What Matters? Annals of Internal Medicine, Volume 179, Issue 10, Page 1489-1491, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Expediting Access to Biosimilars: Assessing the U.S. Food and Drug Administration’s Revised Approach on Comparative Efficacy Annals of Internal Medicine, Volume 179, Issue 10, Page 1492-1493, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Peer-Unreviewed: When the Thread Replaces the Paper Annals of Internal Medicine, Volume 179, Issue 10, Page 1494-1495, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Health Inequities Training Threatened by Revised Liaison Committee on Medical Education Standards Annals of Internal Medicine, Volume 179, Issue 10, Page 1496-1497, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Artificial Intelligence and the Risk of Self-fulfilling Prophecies Annals of Internal Medicine, Volume 179, Issue 10, Page 1498-1499, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 N-Terminal Pro–B-Type Natriuretic Peptide in Older Adults: Biomarker and Barometer of Biological Aging Annals of Internal Medicine, Volume 179, Issue 10, Page 1500-1501, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Both Paternal and Maternal Nutrition Status Matter: An Exemplar From Folate and Vitamin B12 in Association With Risks for Birth Defects Annals of Internal Medicine, Volume 179, Issue 10, Page 1502-1503, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Ethical Oversight of Randomized Quality Improvement Trials: A Pragmatic Approach Annals of Internal Medicine, Volume 179, Issue 10, Page 1504-1505, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Super Mario Soldiers Annals of Internal Medicine, Volume 179, Issue 10, Page 1506-1507, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 “When I Was a Resident …” Annals of Internal Medicine, Volume 179, Issue 10, Page 1508, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 The Doctor in the Waiting Room Annals of Internal Medicine, Volume 179, Issue 10, Page 1509-1510, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Still, We Return Annals of Internal Medicine, Volume 179, Issue 10, Page 1511-1512, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Benzodiazepine Prescriptions to Older Adults in the United States, 2015 to 2024 Annals of Internal Medicine, Volume 179, Issue 10, Page 1514-1519, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Provision of Onsite Prenatal Care Services at U.S. Federally Qualified Health Centers Annals of Internal Medicine, Volume 179, Issue 10, Page 1519-1522, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Quality Indicators for Diabetes in Adults Annals of Internal Medicine, Volume 179, Issue 10, Page 1524, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
Ono Pharma’s ONO-1110 failed five Phase 2 trials, leading to the discontinuation of development in depression and social anxiety. Work will continue for three pain indications.
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial The disclosure—which came ahead of a presentation of data from the Phase 1 Breakfree-2 study at the ACTRIMS-ECTRIMS meeting—follows Bristol Myers Squibb’s late summer revelation that it had paused certain trials of zolacabtagene autoleucel.
ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3 A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in June in fewer patients.
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.
Rapport ekes out bipolar mania win as lead asset ‘just hits’ in mid-stage trial Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential pipeline-in-a-product—this time showing improvement in symptoms of bipolar mania.
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolstering the company’s push beyond its HIV portfolio.
As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone.
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively.
Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop Arrowhead Pharmaceuticals’ siRNA candidate achieved “compelling” tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperformother blood-brain barrier platforms, according to Stifel.
Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggled Revolution Medicines’ recently approved drug showed a 24% overall response rate and a high rate of side effects in patients whose cancer has a G12D mutation, reinforcing Mizuho’s view that a more specific agent such as Verastem Oncology’s VS-7375 “should come first for G12D patients.”
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain Diagonal Therapeutics Appoints Industry Veteran Jeremy Bender, Ph.D., M.B.A., as Chair of the Board of Directors Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB) TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd. Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes Adjuvia Therapeutics Initiates Phase 1 Clinical Trial of ATI-105 for Friedreich’s Ataxia Caravel Bio Secures $1.2M NSF Phase II Grant to Scale the Data Engine Behind Its Full-Stack Protein Engineering Platform Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis Blue Lake Biotechnology Secures $5 Million Grant to Support Ongoing Pediatric Phase 1/2a Clinical Trial of Intranasal RSV Vaccine Candidate Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Remix Therapeutics Selected for Late-Breaking Oral Presentation at the 38th EORTC-NCI-AACR Symposium Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International Beeline Medicines to Present Results from the Phase 2 Trial of Afimetoran in Systemic Lupus Erythematosus as a Late-Breaking Oral Presentation at ACR Convergence 2026 As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome |
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first TROP2-directed ADC to do so in this setting, Merck told BioSpace.
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer When used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintenance setting—a potentially “practice-changing” outcome, according to Truist Securities.
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial Extending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising questions about its commercial prospects.
Roivant’s TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a pair of Phase 3 non-infectious uveitis trials, leading analysts to say the candidate “looked superior to Humira.”
Epkinly data only one of Genmab’s make-or-break readouts ahead of steep sales erosion Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.
Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light.
Veradermics’ minoxidil pill improves hair coverage in men in Phase 3 In the wake of a successful IPO and strong stock growth throughout the year, Veradermics now has late-stage data to support a regulatory package for its hair loss pill.
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment While Oppenheimer doesn’t see the Phase 3 stumble of VQW-765 as highly detrimental to Vanda Pharmaceuticals, the analyst nevertheless believes the stakes are now higher for the company’s planned Q4 readout for Nereus in GLP-1-induced vomiting.
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain Merakris Advances Potentially Pivotal MTX-001 Phase 2/3 Strategy Following FDA Pre-IND Meeting Henlius reports positive results from ASTRIDE U.S. bridging study for serplulimab in combination with chemotherapy for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 Chidamide Plus Nivolumab Shows Potential as New Standard of Care in Advanced Melanoma, Reducing Disease Progression Risk by 27% in Global Phase 3 Trial CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) Ambros Therapeutics Announces Planned Interim Analysis of Phase 3 Clinical Trial Following FDA Feedback Initiation of a Phase III Clinical Study of BON-001 for Nausea and Vomiting of Pregnancy in Japan Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026 Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis Serapha Bio Announces Positive Interim Safety and Efficacy Data from the SERP-01 Investigator-Initiated Trial Presented at the ERS Alpha-1 Antitrypsin Conference 2026 AL-S Pharma Reports New AP-101 Phase 2 Weight Data and Outlines Phase 3 Clinical Trial in ALS at 2026 NEALS Annual Meeting Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer |
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
Analysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025 Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking prior to the presentation and antibody-drug conjugate sac-TMT making a splash in endometrial cancer; Bristol Myers Squibb revealed the death of a patient with multiple sclerosis in an early-stage trial of zola-cel; and pharma is on track to easily surpass last year’s deal count.
Biotechs going to market alone must learn to go global Drug developers increasingly have the option of seeking regulatory approval and commercializing a medicine themselves, rather than accepting an early exit offer. Doing so requires a worldwide strategy.
EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines In a Phase 1 study, treatment with Incyte’s KRAS G12D inhibitor in combination with standard-of-care chemotherapy elicited an 89% confirmed objective response rate in patients with a type of pancreatic ductal adenocarcinoma, leading analysts to draw comparisons with Revolution Medicines’ zoldonrasib.
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first TROP2-directed ADC to do so in this setting, Merck told BioSpace.
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last week spurred a stock selloff for both partners.
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer When used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintenance setting—a potentially “practice-changing” outcome, according to Truist Securities.
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial Extending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.
Australia’s clinical trial advantage gains ground amid U.S. uncertainty CROs cite faster startup timelines, regulatory predictability and tax incentives as reasons for growing interest in Australia. State investments in manufacturing, translational research and advanced therapies aim to expand that advantage into a broader biotech ecosystem. The question remains whether Australia can support drug development at broader scale.
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial The disclosure—which came ahead of a presentation of data from the Phase 1 Breakfree-2 study at the ACTRIMS-ECTRIMS meeting—follows Bristol Myers Squibb’s late summer revelation that it had paused certain trials of zolacabtagene autoleucel.
Blue Lake Biotechnology Secures $5 Million Grant to Support Ongoing Pediatric Phase 1/2a Clinical Trial of Intranasal RSV Vaccine Candidate Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis Lilly’s retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic’s highest approved dose in head-to-head trial Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer Remix Therapeutics Selected for Late-Breaking Oral Presentation at the 38th EORTC-NCI-AACR Symposium Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026 Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis Beeline Medicines to Present Results from the Phase 2 Trial of Afimetoran in Systemic Lupus Erythematosus as a Late-Breaking Oral Presentation at ACR Convergence 2026 Alterome Therapeutics to Present First Clinical Data from Phase 1/1b Trial of ALTA3263 in KRAS-Mutant Advanced Solid Tumors in Late-Breaking Presentation at the 38th EORTC-NCI-AACR Symposium AcuraStem Receives Hoffman ALS Clinical Trial Award to Support Phase 1 Trial of AS-241, the Clinical Candidate of its UNC13A Program Forlong Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of Subcutaneous FL115 (IL-15 Superagonist) in Australia Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides Syncromune Reports Long-Term Data from Phase 1 Study in Metastatic Prostate Cancer with Investigational SYNC-T Therapy SV-102 |
|
|
| |||
|
FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations
On October 26, 2026, the Food and Drug Administration (FDA) approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test.
Mon, 26 Oct 2026 00:00:02 -0700
FDA grants traditional approval for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication On October 16, 2026, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥13 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Thu, 22 Oct 2026 00:00:02 -0700
FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer On October 19, 2026, the Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized test for solid tumors.
Mon, 19 Oct 2026 00:00:02 -0700
FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors to include patients with high-grade papillary-only tumors.
Wed, 14 Oct 2026 00:00:02 -0700
FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
Thu, 08 Oct 2026 00:00:02 -0700
FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
Wed, 07 Oct 2026 00:00:02 -0700
FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.
Fri, 02 Oct 2026 00:00:02 -0700
FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Thu, 24 Sep 2026 00:00:02 -0700
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.
Wed, 23 Sep 2026 00:00:02 -0700
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.
Fri, 18 Sep 2026 00:00:02 -0700
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Wed, 09 Sep 2026 00:00:02 -0700
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
Fri, 04 Sep 2026 00:00:02 -0700
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Wed, 26 Aug 2026 00:00:02 -0700
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma Tue, 25 Aug 2026 00:00:02 -0700
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 13 Aug 2026 00:00:02 -0700
FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Thu, 06 Aug 2026 00:00:02 -0700
FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
Fri, 31 Jul 2026 00:00:02 -0700
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Wed, 22 Jul 2026 00:00:02 -0700
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
Tue, 14 Jul 2026 00:00:02 -0700
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
Tue, 14 Jul 2026 00:00:02 -0700
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
Fri, 10 Jul 2026 00:00:02 -0700
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.
Thu, 09 Jul 2026 00:00:02 -0700
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
Tue, 30 Jun 2026 00:00:02 -0700
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
Wed, 24 Jun 2026 00:00:02 -0700
|
Harmful gases including carcinogens produced during transurethral resection of the prostate and vaporization.
Int J Urol. 2010 Nov;17(11):944-9. doi: 10.1111/j.1442-2042.2010.02636.x. Epub 2010 Sep 29. Chung YJ, Lee SK, Han SH, Zhao C, Kim MK, Park SC, Park JK Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology. 2020 Oct 20;95(16):e2295-e2304. doi: 10.1212/WNL.0000000000010643. Epub 2020 Sep 2. Weigand AJ, Bondi MW, Thomas KR, Campbell NL, Galasko DR, Salmon DP, Sewell D, Brewer JB, Feldman HH, Delano-Wood L; Alzheimer's Disease Neuroimaging Initiative 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan. Lancet. 2026 Oct 24:S0140-6736(26)01782-4. doi: 10.1016/S0140-6736(26)01782-4. Sakakida T, Taniguchi H, Asayama M, Suwa Y, Shimura T, Mitani S, Makiyama A, Arai H, Matsuoka H, Yokota M, Takano Y, Kato K, Oda H, Kajiwara T, Ogawa K, Shibata N, Sawada K, Yomoda T, Kudo T, Okuda H, Okumura Y, Tanaka C, Nakamura M, Tsuda T, Kitajima T, Tsukuda H, Shinozaki E, Furuta M, Kashiwada T, Okuya K, Mushiake H, Hasegawa J, Nihei K, Mizushima T, Mine T, Mizukami T, Kudo C, Mishima A, Murotani K, Masuishi T; PRABITAS investigators Taurine lowers inflammaging by regulating the NLRP3 inflammasome in macrophages. Cell. 2026 Oct 23:S0092-8674(26)01207-9. doi: 10.1016/j.cell.2026.09.061. Guan C, Ryu S, Dong M, Zhu Y, Maeda R, Youm YH, Mohanty S, Kim HH, Orliaguet L, Dlugos T, Smith SR, Ravussin E, Onyuru J, Hoffman HM, Siebel S, Wang A, Wang Y, Kluger Y, Shaw AC, Kanneganti TD, LeBrasseur N, Sugiura Y, Dixit VD Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2026 Oct 24. doi: 10.1056/NEJMoa2609482. Pérol M, Yoshida T, Ahn MJ, Gay CM, Schuler M, Liu H, Sezer A, Bilici A, Korantzis I, Lim SM, Otsubo K, Juan-Vidal O, Chen Y, Schvartsman G, Wang H, Dingemans AC, Clarke JM, Desai A, Marigil M, Chen Y, Abidi B, Wang J, Sands J; DeLLphi-305 Investigators A general scaling law reveals why the largest animals are not the fastest. Nat Ecol Evol. 2017 Aug;1(8):1116-1122. doi: 10.1038/s41559-017-0241-4. Epub 2017 Jul 17. Hirt MR, Jetz W, Rall BC, Brose U Bile Acid Dysregulation Is Intrinsically Related to Cachexia in Tumor-Bearing Mice. Cancers (Basel). 2021 Dec 20;13(24):6389. doi: 10.3390/cancers13246389. Thibaut MM, Gillard J, Dolly A, Roumain M, Leclercq IA, Delzenne NM, Muccioli GG, Bindels LB Last appearance of Homo erectus at Ngandong, Java, 117,000-108,000 years ago. Nature. 2020 Jan;577(7790):381-385. doi: 10.1038/s41586-019-1863-2. Epub 2019 Dec 18. Rizal Y, Westaway KE, Zaim Y, van den Bergh GD, Bettis EA 3rd, Morwood MJ, Huffman OF, Grün R, Joannes-Boyau R, Bailey RM, Sidarto, Westaway MC, Kurniawan I, Moore MW, Storey M, Aziz F, Suminto, Zhao JX, Aswan, Sipola ME, Larick R, Zonneveld JP, Scott R, Putt S, Ciochon RL Creatine supplementation effects on cognition, sleep, and menopause symptoms in response to six weeks of high-intensity resistance training in perimenopausal females. Eur J Appl Physiol. 2026 Oct 24. doi: 10.1007/s00421-026-06481-6. Baker PA, DelBiondo GM, Kelly CG, Johnson WM, Grosicki GJ, Smith-Ryan AE Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial. Ann Oncol. 2026 Oct 25:S0923-7534(26)08070-1. doi: 10.1016/j.annonc.2026.10.1280. Cercek A, Bachet JB, Folprecht G, Bando H, Seligmann J, Starling N, Riesco-Martinez MC, Alfonso PG, Smith D, Salvatore L, Flores EG, Mitry E, Chen E, Castillon JC, Morano F, Keränen SR, Aubin F, López CL, Lonardi S, Buchschacher G Jr, Roderburg C, Gerlinger M, Modest D, Heinemann V, Goetze TO, Kato T, Park YS, Perkins G, Lemay F, Vickers M, Szijgyarto Z, Stjepanovic N, Haftchenary S, Diaz LA Jnr, Roodhart JML Perforin triggers iron-induced mitochondrial damage to drive ferroptosis and anti-tumor immunity. Cell. 2026 Oct 23:S0092-8674(26)01208-0. doi: 10.1016/j.cell.2026.09.062. Bell HN, Nair K, Tison K, Liao P, Lei H, El-Derany MO, Yisimayi A, Zhang H, Rebernick R, Wang W, Adachi Y, Castillo C, Das NK, An J, Sutton VR, Lin X, Lin H, Wang X, Li Y, Vatan L, Aboud A, Wei S, Gijon M, Goodwin S, Shah YM, Kryczek I, Trapani JA, Barroso M, Lieberman J, Zou W The bidirectional predictive association between methamphetamine use and depression. Addiction. 2026 Oct 24. doi: 10.1111/add.70668. Tran LT, Clare PJ, Degenhardt L, Lubman DI, Berk M, Carter G, Arunogiri S, Turner A, Dean OM, Kelly P, McKetin R Toxicological alert: Exposure to glycidyl methacrylate and cancer risk. Toxicol Ind Health. 2020 Dec;36(12):937-939. doi: 10.1177/0748233720957816. Epub 2020 Nov 6. Fernandes BJD, Couto RD Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. JAMA. 2026 Oct 24:e2619921. doi: 10.1001/jama.2026.19921. Yang Y, Yang C, Wang Y, Rawee P, Cases A, Leaf DE, Del Vecchio L, Muka T, Heerspink HJL, Gansevoort RT, Eisenga MF Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy. N Engl J Med. 2026 Oct 25. doi: 10.1056/NEJMoa2611335. Lu S, Girard N, Yang JC, Shepherd FA, Dong X, Arulananda S, Metro G, Hayashi H, Bonanno L, Kim YJ, Liu Z, Ahn MJ, Sun Y, Le TV, Novello S, Kim SW, Zhao Y, Nguyen P, Brandão M, Wang Y, Haigentz M, Misch D, Provencio Pulla M, Huang WT, Baldotto C, Tatangelo M, Lindsay CR, Hartmaier RJ, Lolo R, Swaminathan B, Gont A, Esposito FM, Okuma Y; SAFFRON Investigators Empagliflozin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Randomized Controlled Trial. J Am Soc Nephrol. 2026 Oct 24. doi: 10.1681/ASN.0000001271. Seliger SL, Gitomer B, You Z, Wang W, Ostrow A, Andrews E, Diggs C, George D, West M, Nowak KL, Watnick T, Chonchol M Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC. N Engl J Med. 2026 Oct 25. doi: 10.1056/NEJMoa2611280. Zhou F, Meng X, Ding Q, Zhang P, Liang W, Guo S, Yu Y, Yao W, Fan Y, Pu X, Liu C, Cui J, Chen P, Zhong H, Wang Y, Huang Z, Xu Z, Dong X, Yi T, Hu Y, Wang Q, Chen B, Wang H, Sun L, He L, Zheng W, Wang Y, Zhang X, Yao Y, Li Y, Yang Z, Ye F, Song X, Zhou M, Yin L, Qing Y, Jin X, Ge J, Zhou C Dynamic force sensing by bone delays aging and extends lifespan. Cell Metab. 2026 Oct 23:S1550-4131(26)00433-X. doi: 10.1016/j.cmet.2026.09.020. Zhang Z, Cai Z, Liu S, Chu Y, Jiang Z, Zhang W, Pan Y, Lin Y, Wei X, Chen J, Huangfu J, Nan B, Zhou Y, Hu L, Liang W, Zou Z, Huang M, Lu S, Lu D, Bai X Expression of insulin-like growth factor 1 and receptor in ischemic rats treated with human marrow stromal cells. Brain Res. 2004 Dec 24;1030(1):19-27. doi: 10.1016/j.brainres.2004.09.061. Zhang J, Li Y, Chen J, Yang M, Katakowski M, Lu M, Chopp M BAK and BAX form a multiprotein complex to drive mtDNA efflux and caspase-independent cell death. Science. 2026 Oct 22;394(6822):eaea2181. doi: 10.1126/science.aea2181. Epub 2026 Oct 22. Yang S, Kim H, Liao G, Ta N, Tu HC, Ramani S, Chen CY, Li ZY, Tanno N, Hsieh JJ, Cheng EH |
||